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In recent years, Point of Care (POCT) or Point of Need tests (PONT) have been 
established in order to provide accurate and rapid diagnostics directly at field level or 
at site of outbreaks. These assays can help decision makers to take the right action 
without delay. Typically, POCT and PONT rely on the genomic identification of 
pathogens or tracking its immunological fingerprint. Recognition of a pathogen’s 
genome in the field using molecular assays highly depends on the efficiency of nucleic 
acid extraction. Moreover, the sensitivity and specificity of molecular assays rely on 
previous knowledge of DNA or RNA sequences. 
Classical immunological based tests i. e. whole antigen based ELISA lack specificity 
due to high antigen homology within the respective genus of pathogen as seen, for 
instance, in flaviviruses.  
To address these drawbacks, this PhD work applied three different approaches: a rapid 
nucleic acid extraction method, metagenomic diagnostics and peptide microarray. 
During the course of this work a protocol for the rapid extraction of nucleic acids of 
Gram-positive bacteria was developed employing magnetic bead based reverse 
purification technology. The extraction was carried out within 20 minutes. In 
combination with the recombinase polymerase amplification assay, a 90.9 % clinical 
sensitivity and 100% clinical specificity were reached. 
A protocol for the rapid and field applicable identification of RNA viruses to determine 
the causative agent in an outbreak by diagnostic metagenomics was implemented. 
Therefore, multiple displacement isothermal amplification and nanopore sequencing 
were combined to test a mock sample containing Zika virus (ZIKV). The whole 
procedure was conducted in less than seven hours including sample preparation. 
Presence of ZIKV sequences within the produced reads was determined by offline 
BLAST search. The procedure was further developed for rapid serotyping of foot and 
mouth disease virus (FMDV) relying on nanopore sequencing and offline BLAST 
search. The offline BLAST search was highly successful in categorizing seven FMDV 
serotypes by using the P1 region (specificity: 98.3%) instead of whole genome 
(24.8%), P2 (23.6%) or P3 (21.4%) regions.  
A peptide microarray was used to identify a bundle of Zika Virus (ZIKV) specific 
antibody targets for the differentiation of other flaviviruses. Briefly, a total of 1643 
overlapping oligopeptides were synthesized and printed onto glass slides. The 
oligopeptides cover the whole polyproteins of ZIKV originated from Africa, Brazil, USA 
Summary 
 VI 
and French Polynesia. The ZIKV scanning microarray chips were applied to examine 
three human serum pools from Zika outbreaks in Senegal and Cape Verde, in Brazil, 
and from overseas travellers returning to the EU as well as a pool of well described 
sera from patients that had suffered from dengue, yellow fever, tick-borne encephalitis 
or West Nile virus infections. Altogether, sixty-eight antibody target regions were 
identified, most of them previously unknown, from which thirteen could be classified as 
potentially ZIKV specific.  
While the fast and sensitive extraction of DNA in the field was shown to enable genomic 
assays at PON, the two sequencing protocols have the potential to provide field 
applicable metagenomic diagnostics at point of need as workflows were performed in 
a mobile suitcase laboratory. The results obtained by the peptide microarray can be 
seen as a founding set of analytical tools for serological discrimination of ZIKV from 
other flaviviruses. 
In conclusion, this PhD study paves the way for reliable POCT and PONT and 
represents an example of research at One Health level, in which the health of human, 
animal and environment matter.  
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Chapter I: General Introduction 
Background  
Many different microorganisms such as bacteria, viruses, fungi or parasites are 
existing in the environment. Most of them are important to maintain the ecosystem on 
earth, however, some of them are pathogenic and cause infectious diseases in both 
human and animals. Diseases that are transmitted from animal to humans are called 
zoonotic [1]. Infectious diseases are one of the major reasons for death especially in 
the low and middle-income regions of the world. In addition, there are high economic 
losses due to diseased persons or animals [2, 3]. The World Organization for Animal 
Health (OIE) estimates the average economic losses in animals are around 20 percent 
[4]. A profound surveillance system is one of the main factors to prevent the spread of 
infectious diseases [5] which can only be archived with highly advanced diagnostics. 
The current diagnostic approaches rely on centralised reference laboratories with high 
throughput, due to the need of complex and expensive devices. Point-of-Care testing 
(POCT) describes the identification of pathogens near the patient with a fast turn-
around time and the potential to immediately change in the health management [6]. 
While the term POCT is used for human patients and samples, Point-of-Need testing 
(PONT) has a broader meaning including also on-site testing of environment, animals, 
and food samples, although this term is not clearly defined yet. The World Health 
Organisation (WHO) formulated the characteristics of POCT and PONT as affordable, 
sensitive, specific, user friendly, robust and rapid, equipment free, and deliverable to 
those who need them (ASSURED criteria, Table 1) [7].  
 




U User-friendly  
R Robust and rapid  
E Equipment-free 
D Deliverable to those who need them 
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Examples for rapid diagnostics in the field are the POCTs for malaria and human 
immunodeficiency viruses (HIV) as well as the PONTs for Bluetongue virus [8], 
Schmallenberg virus [9], Bovine diarrhoea virus [9], Foot and Mouth disease virus 
(FMDV) [10], and the Lumpy Skin Disease Virus [11]. As a consequence, disease 
control as well as change in treatment and care was achieved [12, 13] particularly, in 
regions where stable electricity supply, highly trained personal or specialized devices 
are not available [12]. Most POCT and PONT rely on immuno-techniques to detect 
antigens or antibodies, but methods for the identification of the pathogen at molecular 
level are on the rise [14]. Details about these methods are mentioned below. 
 
Immunoassays 
Immunoassays are based on binding of an antibody and an antigen to each other. For 
detection, the antigen is immobilized on a solid phase and bound to a specific primary 
antibody which is recognized by a secondary labelled antibody. This is named indirect 
immunoassay [15]. In a competitive assay, the target molecule competes with labelled 
antigens or antibodies in binding to the immobilized molecules. Another method is the 
so-called sandwich assay. Here, the target antigen is fixed between two of the same 
immobilization and identification molecules. [16].  
Labelling of the secondary antibodies is accomplished for instance by enzymes (in 
case of enzyme-linked immunosorbent assay, ELISA), gold nanoparticles or silver 
nanoparticles lateral flow immunoassays (LFIA, [17]). ELISA has long and complex 
protocols or requires highly sophisticated laboratory equipment, while the most 
employed technique for POC and PON applications is the LFIA. 
 
Lateral flow immunoassays for the detection of antigens or antibodies 
The first LFIA were brought into the market in the early 1980s, since then, many tests 
have been developed [18]. LFIA is able to detect pathogen specific antigens and/or 
antibodies. Lateral flow assays are among the simplest equipment-free methods as 
they are performed in a small disposable cartridge (Figure 1). LFIA do not require 
pipetting, washing steps and can be performed by untrained personal. In addition, no 
cold chain is required [19]. The results can be obtained in 10-30 minutes.  
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Figure 1: Structure and type of a Lateral Flow Immunoassay. (Panel A) schematic design: 1, sample pad; 2, 
conjugate pad; 3, membrane; 4, test line; 5, control line; 6, adsorbent pad. (Panel B) indirect lateral flow 
immunoassay. (Panel C) competitive lateral flow immunoassay (Panel D) sandwich lateral flow immunoassay. 
The principle of a LFIA is as follows: the sample is brought onto the sample pad and 
flows in the opposite direction by adsorption. While the sample passes the conjugate 
pad, a labelled target specific antibody binds to the target molecule in the sample 
(antigen or antibody). Afterwards, the labelled antibody-target complex is immobilized 
to the membrane by a specific capture molecule (antibody or antigen) adhered to the 
membrane at the test line. The unbound labelled antibodies are captured at a control 
line by immobilized antibodies. In case of a positive sample, the accumulation of the 
labelled antibodies leads to a colouration of both test lines. In case of a negative 
sample only the control line is coloured. The adsorbent pad takes up the excess liquid 
[20, 21]. In case of pathogens or targets, which are not suitable for the indirect or 
sandwich designed LFIA, a competitive layout can be applied. This results in only one 
coloured test line in case of a positive test [20].  
Recently, multiplex LFIA have been developed detecting multiple targets in a single 
test [22, 23]. Paper-based micro fluid devices (µPAD) are yet another development of 
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the lateral flow technique. Here, the sample is guided by hydrophobic channels [24]. 
This design enables more sophisticated applications like the combination of multiple 
serological assays in a single device [25-27]. 
Sensitivity and specificity of LFIA highly depend on labelling and binding affinity of the 
tested biomolecules [17, 28]. A high concentration of molecules is necessary to 
achieve positive results. Therefore, LFIA will produce a negative result, when testing 
samples containing only few target molecules. Moreover, in some occasions sample 
preparation is necessary since the test design only allows liquid non-viscous samples 
[29]. Quantification of targets is not possible using the LFIA.  
 
Methods for the identification of pathogens at the genomic level  
Nucleic acid amplification methods have the advantage of being highly sensitive as 
opposed to immunological assays due to the amplification step. DNA is amplified using 
with cycling methods such as Polymerase Chain reaction (PCR) or isothermal 
amplification.  
 
Polymerase chain reaction 
The Polymerase Chain Reaction (PCR) as the first molecular assay was developed by 
Kary B. Mullis in 1983 [30]. This method utilizes two oligonucleotides (primers) each 
complementary to one of the target DNA strands spanning the amplified region. The 
primers act as trigger for the synthesis of the complementary strands by a polymerase. 
Amplification of the target sequence is promoted by different heat steps. In the 
denaturation step (95°C), the double strand of the target DNA is separated. In the 
annealing step (50-75°C), the primers hybridize to the target region in the single strand 
DNA. Final extension takes place using the polymerase at 72-78°C. Together, the 
three steps form a cycle. A single PCR run consists out of 30-40 cycles [31]. Real-time 
detection of amplification is mostly achieved with a 5′ fluorophore and 3′ quencher 
labelled probe complementary to the target sequence [32]. 
 
Isothermal amplification 
Isothermal amplification assays have the advantage of employing a constant reaction 
temperature for the amplification. This offers more utility in the field due to the use of 
portable heat sources and shorter run time in comparison to the cycle driven PCR [33, 
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34]. Moreover, most isothermal methods are known to be resistant to inhibitors existing 
in complex samples like blood [35]. Several different methods for isothermal 
amplification have been developed in the past years (Table 2). From these methods, 
the two most evolving techniques are the Loop-mediated Isothermal Amplification 
(LAMP, Figure 2) and the Recombinase Polymerase Amplification (RPA, Figure 3). 
The features of both methods are shown in Table 3. 
 











37 60 2 - 
Rolling Circle Amplification 
(RCA) 
37 90 1,2 or >2 +/- 
Recombinase Polymerase 
Amplification (RPA) 
39-42 3-10 2 + 
Nucleic Acid Sequence 
Based Amplification 
(NASBA) 




60 2-5 2 +/- 
Loop-mediated isothermal 
Amplification (LAMP) 
60-65 60 6 +/- 
+ use of probe for real-time detection possible          +/- use of probe possible, but usually not applied 
- use of probe not possible 
 
Table 3: Features of Loop-mediated Isothermal Amplification (LAMP) and Recombinase Polymerase 
Amplification (RPA). 






portable heat source 
ü ü 
easy to implement in field applications 
ü 
ü 
fast result  ü 
pair of primers  ü 
simple assay design  ü 
highly resistant to inhibitors  ü 
long storage of reagents at room temperature  ü 
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Figure 2: The Loop-mediated isothermal Amplification (LAMP) is based on a so called auto-cycling strand 
displacement DNA synthesis using a strand displacing DNA polymerase and two pairs of target specific primers. 
The inner primers contain two sequences each corresponding to the sense and anti-sense (rc) strand of the target 
DNA, respectively, linked with a TTTT-spacer. The inner primers initiate a complementary synthesis of the target 
DNA while the outer primers (FP1 and RP3) initiate a strand-displacement synthesis resulting in the release single-
stranded DNA linked by inner primers. The single-stranded DNA forms stem-loops by self-annealing of the 
corresponding sequences and acts as template for exponential amplification [36].  
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Figure 3: The Recombinase Polymerase Amplification (A) employs a recombinase enzyme, a single-stranded 
binding protein, a strand-displacing (ss-DNA) polymerase, and a pair of target specific primers. The primers form 
together with the recombinase enzyme the Recombinase-Primer complex which allows them to invade the double-
stranded helix of the target DNA at the respective recognition site. The strand-displacing polymerase elongates the 
primers while the ss-DNA binding protein stabilized the displaced strand in order to prevent self-annealing and 
ejection of the primers by branch migration. Real-time detection of amplification (B) is achieved by a sequence 
specific probe consisting out of a tetrahydrofuran abasic–site mimic (THF) flanked by fluorophore and quencher 
labelled nucleotides as well as an extension blocker at the 3´-end. As the probe pairs with the complimentary 
sequence, a double-strand specific exonuclease slices the THF and the fluorophore is dissociated resulting in a 
signal [37]. 
Equipment free nucleic acid amplification 
The implementation of equipment free nucleic acid amplification at POC and PON is 
extremely challenging [38]. Even LAMP assays [38-40] are still in need of a heating 
source. Nevertheless, to overcome the required power supply for LAMP reaction, 
LaBarre et al. developed a portable heating cartridge based on exothermal-reaction 
and engineered phase-change material. Heat is generated by the reaction of calcium 
oxide and water. To keep the temperature in the optimal range, a fat-based compound 
with a specific heat capacity and melting point (65°C) is applied. Beside LAMP, this 
cartridge is also suitable for other isothermal reaction like RPA or the Nicking Enzyme 
Amplification Reaction (NEAR [41, 42]).  
While in LAMP assays nucleic amplification results in a turbid reaction mix, the 
equipment free detection of amplification remains challenging in other isothermal 
techniques. However, since LAMP relies on multiple primers, an unspecific 
amplification can happen, probably due to cis and trans priming among the single 
primers. Therefore, specific amplicon detection is also necessary [43]. 
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To provide a simple and inexpensive read-out of the different amplification methods, 
nucleic acid lateral flow (immuno-) assays (NALFA/NALFIA) were applied [44]. These 
assays are mainly based on the capture of tagged amplicons or detection of amplicons 
in a sandwich-format [29]. The use of lateral flow technique liberates from the need of 
sophisticated devices (e.g. fluorescence reader). In some studies, isothermal 
amplifications were shown to operate on paper-based devices. While paper-based 
RCA [45] works on room temperature without equipment, RPA was also conducted 
equipment-free using the body heat for incubation combined with a lateral flow-based 
detection of the tagged amplicons. The principle of RPA lateral flow detection is shown 
in Figure 4, [46-48]). 
 
Figure 4: Detection of RPA amplicon in a lateral flow format. The use of a 5`end Biotin labelled reverse primer 
in the RPA reaction leads to an antigenic tagged reverse strand. When the 5´FAM-labbeled probe binds to the 
complimentary strand a double-strand specific endonuclease slices the THF. The extension blocker is released and 
the remaining oligonucleotide can act as primer resulting in a FAM and Biotin labelled amplicon (A), which can be 
detected in a lateral flow sandwich format (B,[49]). 
 
Metagenomic diagnostics as a tool for outbreak identification 
Metagenomic diagnostics is the identification of pathogens by metagenomic 
information obtained from nucleic acid sequencing [50]. This approach is based on the 
sequencing and identification of either all the nucleic acids present in the sample 
(shotgun metagenomics) or a particular group of previously generated amplicons 
(targeted-amplicon sequencing) [51].  
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The molecular detection through PCR or isothermal amplification of a pathogen 
requires a known target nucleic acid sequence. Thus, in an outbreak of unknown 
cause, selection of the right molecular assay upon the clinical signs is challenging and 
a novel pathogen or variants of known infectious agent may remain undetected. 
Metagenomic diagnostics overcomes this problem by sequencing and identifying all of 
the nucleic acids within the sample and thereby preparing for simpler diagnostic 
testing. Also, information about epidemiology and transmission route can be achieved 
[52]. However, the performance of this method strongly relies on the used genome 
database and depth of sequence analysis as well as on the amount of generated reads 
[53]. The major drawback of meta genomic diagnostics are the high costs per 
sequencing sample and the relatively long turnover times [52].  
Sequencing methods require heavy and complex devices. However, the introduction 
of nanopore sequencing to the market by Oxford Nanopore Technologies (ONT, 
Oxford, UK) allows third-generation sequencing at point of need due to small portable 
sequencing devices (Figure 5, [54]). The great utility of nanopore sequencing at point 
of need was proven by identification of pathogens direct from clinical and tick samples 
[55, 56] as well as during the surveillance of Ebola, Lassa, Yellow Fever, and Zika 
outbreaks in West-Africa and South-America [57-60]. 
 
 
Figure 5: A: MinION sequencing device (ONT, Oxford, UK); B: Principle of nanopore sequencing. A protein 
pore is embedded in a membrane set under a certain electrical current. As the DNA molecule passes through the 
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Why is every method important?  
Immunoassays are an inexpensive, robust, and simple way to use for the detection of 
antibodies. Since different types of antibodies can be detectable several days or up to 
years in the blood [61], the immunoassays represent an easy way for surveillance of 
previous and ongoing chronic infection. However, the identification of a disease based 
solely on antibody detection may lead to a false assumption about the diseased status 
of the individual. During persistent infections a detection of antigen and antibody is 
normally possible over a long period of time, a latent infection (as a special case of 
persistent infections) is characterized by a very low antigen concentrations but high 
antibody level (for definitions see Table 4, [62]). In the latter case, nucleic acid 
amplification assays are needed as they can detect a low number of genomes with 
high specificity, which is especially helpful as for some chronic infections, the 
concentration of pathogens, antigens and antibodies varies over the time [63]. Thus, 
the combination of immunological and genomic methods is necessary. On the other 
hand, as the immune response towards a disease starts a few days post infection and 
reaches the highest point around two weeks post infection [64], the detection of an 
acute infection is not possible solely based on antibodies. When the pathogen exists 
with a low concentration in the sample or is detectable for a short period of time (like 
swine influenza virus [65]), nucleic acid amplification assays are a good tool for 
diagnosis of such diseases. 
 
Table 4: Possibility of Antigen/Antibody detection in different types of infection [62]. 
Type of infection Detection of antigens Detection of antibodies 
acute + - 
persistent + + 
latent - + 
chronic +/- +/- 
+ detection possible, - detection not possible, +/- detection temporarily possible  
 
Solutions for mobile laboratories at point of care and point of need 
The need of on-site diagnostic facilities was demonstrated during the West African 
Ebola outbreak as health systems of the affected countries were overloaded or not 
existing. Mobile laboratories were developed to enable diagnosis during outbreak 
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situations. Their great advantage is the capacity of performing several diagnostic tests 
just as well as a central laboratory while being in the field at the site of an outbreak. 
 
European Mobile Lab  
To overcome the problem of long distances to the central diagnostic laboratories during 
the haemorrhagic fever outbreak in West-Africa, the European Mobile Lab Project 
established a moving laboratory unit in Nigeria, consisting of 27 boxes, each of them 
approximately 20 kg to 30 kg in weight. These boxes contain more than 400 equipment 
items needed to set up a fully functional BSL3 or BSL4 diagnostic laboratory in a tent 
or in a local house. Minimum requirements are at least 28 square meters of space and 
a car for constant energy supply [66].  
 
Mobile Suitcase Laboratory  
Originally developed for the field applicable detection of avian influenza, the mobile 
suitcase laboratory was implemented in Guinea during the time of the West-African 
Ebola outbreak. This PON diagnostics solution consists of two trolley cases, a solar 
panel, a power pack, and an optional glove box. One of the trolley cases is employed 
for nucleic acid extraction as all instruments needed are fixated in the suitcase. The 
second trolley case contains all instruments for the detection of the extracted nucleic 
acid via RPA. The devices are placed on foam covered by a PVC top layer to be 
protected from shocks and to facilitate disinfection. The glove box can be used for 
sample disinfection and nucleic acid extraction in case of BSL3 and BSL4 pathogens. 
All materials, kits, and reagents needed for nucleic acid extraction and isothermal 
amplification are stored in the suitcases. Due to the compact design, the mobile 
suitcase laboratory is easy to operate, also in challenging surroundings [67-69]. 
 
Lab in a Caravan 
Another example for a mobile lab solution is the lab in a caravan. Based on the 
experiences made during the Ebola outbreak in West-Africain 2016, the Zika in Brazil 
Real Time Analysis (ZEBRA) project implemented two labs in caravan. These 
complete BSL 3 laboratories were set up in a trailer and used to collect and sequence 
samples of ZIKV along parts of the Brazilian east coast [70].  
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The Praesens Foundation developed a mobile laboratory implemented in a small truck 
[71]. The mobile laboratory contains a real-time thermocycler and a BSL3 glove box 
for sample preparation. The laboratory is air conditioned and can be hermetically 
sealed by the inside lower air pressure. For communication, Wi-Fi, mobile, and satellite 
connection are implemented. The lab has two batteries for power supply lasting more 
than 72 hours [72]. 
 
Advantage of point of care and point of need diagnostics 
The big advantage of POC and PON diagnostics is the identification of pathogens 
directly at the site of the diseased person or animal with small turnaround times. So, 
the persons responsible for treatment can react more quickly according to the result 
[73]. The ease of international travel and trade are the reasons for global spread of 
many infectious diseases, the use of POCT and PONT at airports, harbours, and 
quarantine stations can prevent the entry of diseases into a country. Furthermore, the 
sample volume needed for the tests is often smaller than in conventional laboratory 
tests [74]. In addition, the use of POCT and PONT can lead to more adherence and 
optimisation of the treatment regimen at the clinical side. Economically, it reduces cost 
for applying unspecific treatment, laboratory equipment, and staff [75]. Routine use of 
POCT and PONT can support the building of broad and comprehensive diagnostic 
infrastructure, especially in low resource settings, as the tests are mostly equipment 
free and only small investments in local facilities are necessary [76]. 
 
Barriers for the success of point of care and point of need tests 
The barriers of success of POCT and PONT often depend on several factors: political, 
regulatory, cultural, economic, or communication and perception [77, 78]. Rasmussen 
et al. found in Guinea a significant negative correlation between the willingness to be 
tested for pathogens and the level of education as well as the stability of the political 
system [79]. In addition, Engel et al. showed that barriers differ between cultures. In 
India, people must go to the diagnostic laboratories by themselves, provide samples 
or receive results there and share them with the person responsible for treatment 
afterwards. This may lead to mistakes in communication of the results since the main 
responsibility is with the patient him or herself, as private and untrained person. In 
contrast, the diagnostics in South Africa are highly centralized. Most mistakes occur 
due to bad communication between involved facilities or persons (misspelled names 
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or lost results), sample transportation problems, breakdown of computer systems, and 
others. All these factors lead to long turn-around times in the diagnostics [80]. 
Normally, prices of tests decrease by time once the tests have entered a broad market 
and in accordance the economic concerns of the users. Nevertheless, other doubts 
like implementation of the test into routine testing, the ease of use, supply, and storage 
stability of the test kits especially in rural areas remain big challenges [81, 82]. 
Additionally, decision maker fear sometimes that the extended use and reliance on 
POCT and PONT among other things may undermine their clinical skills, increase 
unnecessary testing and lead to misleading results [83].  
However, some diseases are restricted to small or poor areas in the world. Thus, in 
vitro diagnostic companies have no economic interest to develop or commercialize a 
diagnostic test for these neglected diseases [84]. 
 
The need for capacity building at the link between human and animal health 
Seventy-five percent of human infectious diseases are zoonotic from animal origin [85]. 
Therefore, diagnostic tools for detecting these infectious agents from both human and 
animals are highly necessary. One of the causes leading to the emergence of 
pathogens in many African countries is bush meat, since a large proportion of the 
population depends on it as nutrition source. Not only the consumption but also the 
processing of the meat can lead to an infection [86]. Also, settlement in forests and 
deforestation are driving factors in the spread of infectious diseases as habitats of 
pathogens´ vectors and reservoirs shrink and start to overlap with areas where 
domesticated animals and people live [87]. The danger of being infected by a zoonotic 
disease is not limited to low resource settings. In general, every person who lives or 
works in close contact to animals is at risk [88]. This is particularly true for people living 
on a farm or together with pets but also for people in contact with wild or zoo animals 
[89]. 
Unfortunately, there is a lack of diagnostic capacity in many regions of the world [90-
92]. For instance, in 2013, only twelve countries in sub-Saharan Africa have 
laboratories accredited to international standards. Ninety-one percent of the 380 
laboratories were located in South-Africa [93]. These numbers show the urgent need 
of diagnostic capacity in sub-Saharan Africa.  
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The potential of Point of Care and point of need diagnostics in natural disasters 
When natural disasters happen, they are often followed by infectious disease 
outbreaks. Normally an outbreak starts during the post-impact phase within the first 
four weeks after the disaster. Depending on the type of the catastrophe, the resulting 
disease differs. For instance, floods are leading more often to mosquito borne 
infections, while earthquakes are correlated with diseases occurring due to 
contaminated food or water sources [94]. The WHO defines a relatively small number 
of diseases. Interviews with experts involved in previous disaster situations revealed 
that there are several important pathogens, which are listed in Table 5 [95]. 
 
Table 5: Important pathogens related with epidemic outbreaks after natural disasters as defined by Brock et 
al. [95] in comparison to pathogens listed by the WHO [96]. 







methicillin-resistant Staphylococcus aureus 
E. coli 
Pseudomonas aeruginosa 




















Human Immunodeficiency virus 
Hepatitis B virus 
Hepatitis C virus 
West Nile virus 
Human T-lymphotropic virus 
Cytomegalovirus  
West-Nile virus 




Hepatitis A  
Hepatitis E 
Measles virus  
Dengue fever virus 
Other pathogens 
Plasmodia species 
Leptospira species  
acute respiratory infections 
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Natural disasters like earthquakes, floods or hurricanes can lead to destruction or 
overloading of the local infrastructure. To face the threat of disease outbreak after a 
disaster, diagnostic tests must be handheld or portable, have fast turn-around times, 
good performance, be capable of multiple pathogen testing, and infectious material 
must be disposable easily [95].  
POCT and PONT, like LFIA or portable nucleic acid amplification systems, have the 
ability to fulfil these requirements and can overcome the pitfalls of demolished 
diagnostic infrastructures. LFIA are small and can be sent fast to the disaster affected 
regions. The low-cost test can be used not only to test diseased individuals but also 
for prevention by testing water and food sources. Tests based on nucleic acid 
amplification can easily be adjusted to several pathogens. This eases the 
implementation of functional diagnostics in a region with destroyed infrastructure [97]. 
 
Why the importance of point of care and point of need testing increases 
While globalisation and international travel progresses, the risk of emerging diseases 
is increasing [98]. Due to nowadays global flight connections, persons, goods, or 
traded animals can reach almost every location in the world within one or two days. 
The incubation times of several important zoonotic and animal diseases with emerging 
potential defined by OIE [99, 100] are longer than the flight time (Table 7).  
 




African Swine Fever virus 5-21 
Suid herpesvirus 1(Aujeszky’s disease) 2-10 
Classical swine fever virus 2-14 
Foot and Mouth Disease virus  2-14 
Influenza viruses  1-4 
Lumpy Skin Disease virus 4-28 
Ebola virus 2-21 
Marburg virus 2-21 
Middle East respiratory syndrome virus 2-14 
Rift valley fever virus 2-6 
Severe acute respiratory syndrome virus 2-7 
Hand, foot, and mouth disease viruses (Enterovirus) 3-6 
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Around 75 percent of all new emerging diseases are zoonotic [85], and many diseases 
cause a similar clinical picture, for instance diarrhoea (20 different pathogens, [101]). 
Thus, tests detecting multiple pathogens across species borders are needed. 
Following the One Health concept, todays diagnostics need to cover a holistic 
approach and acknowledge the connections between human, animal, and 
environmental health [102]. 
 
Aim of the PhD work 
This PhD work addresses the need of the fast identification of the responsible agents 
causing similar clinical symptoms in an outbreak at nucleic acid and antibody level.  
Firstly, a method for the rapid and field applicable nucleic acid extraction from complex 
samples was developed based on magnetic beads and reverse purification technology. 
The Mycobacterium avium subspecies paratuberculosis (MAP) was used as model 
pathogen (Chapter II). ZIKV was employed to establish a field applicable protocol for 
the identification of RNA viruses by diagnostic metagenomics. Further, this protocol 
was adjusted to the rapid serotyping of Foot and Mouth disease virus (FMDV) relying 
on nanopore sequencing and offline BLAST search (Chapter III and IV).  
Finally, a peptide microarray was used to determine a bundle of ZIKV specific antibody 
target regions (ATRs) in order to unearth serological markers for the better 
differentiation of ZIKV in the background of other flaviviruses (Chapter V) with the aim 
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Abstract: The rapid identification of Mycobacterium avium subspecies paratuberculosis (MAP) infected
animals within the herd is essential for preventing the spread of the disease as well as avoiding
human exposure. Although culture is seen as the gold standard, there are various molecular assays
available i.e., polymerase chain reaction (PCR) or isothermal amplification technique (recombinase
polymerase amplification (RPA)) for the detection of MAP. The accuracy of the molecular assays is
highly dependent on the DNA extraction method. In order to establish a rapid point of need system
for the detection of MAP DNA from stool samples, we developed a rapid DNA extraction protocol
(MAP DNA SpeedXtract) specified for use in combination with the RPA. The whole procedure from
“sample in” to “result out” was conducted in a mobile suitcase laboratory. The DNA extraction
is based on reverse purification by magnetic beads, which reduces the required technical demand.
The MAP DNA SpeedXtract was performed within 25 min and only three pipetting steps were
needed. The amplification and detection time were 20 min in RPA. The sensitivity and specificity of
the developed protocol in comparison with the lab-based silica membrane column extraction and
real-time PCR were 90.9% (n = 22) and 100% (n = 23), respectively. In conclusion, we established a
rapid and reliable protocol for the extraction and detection of MAP DNA. All reagents are cold chain
independent. The entire setup is ideal for point of need identification of MAP infected cases.
Keywords: Mycobacterium avium subsp. paratuberculosis; rapid extraction; mobile suitcase laboratory;
SpeedXtract; point of need extraction
1. Introduction
The Mycobacterium avium subspecies paratuberculosis (MAP) as the causing agent for Johne’s
Disease (Paratuberculosis) in ruminants is a Gram-positive, aerobic, non-motile, non-spore-forming
and acid fast bacterium [1]. Clinical signs of John’s disease, such as weight loss, reduction in milk
production and progressing diarrhoea, have an enormous negative impact on the dairy industry [2].
Transmission occurs mainly through the faecal–oral route [3]. The identification of subclinical shedders
is highly necessary to prevent silent spreading of the pathogen within the herd. Faecal culture is
the gold standard for the diagnosis of MAP [4], however it requires at least 12–16 weeks before the
sample can be considered as negative. Alternatively, highly sensitive and specific molecular assays
such as Polymerase Chain Reaction (PCR) [5] or the recently published Recombinase Polymerase
Amplification assay for the detection of MAP (MAP RPA) [6] are available. However, the clinical
Diagnostics 2019, 9, 36; doi:10.3390/diagnostics9020036 www.mdpi.com/journal/diagnostics
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performance of these assays depends strongly on the quality of the extracted DNA [7]. Isolation of MAP
DNA from faecal samples is especially challenging due to the presence of other complex compounds
in the bovine faeces, which can inhibit the amplification process. Moreover, the cell walls of MAP,
containing high numbers of lipophilic molecules and polysaccharides, are not easy to destroy [8–10].
In standard laboratory protocols, physical disruption is applied after adding chaotropic salts and
proteinases to the sample. A lab tube containing silica gel membrane columns is used to obtain a highly
purified DNA after employing several washing and centrifugation steps [7,11,12]. These procedures
are often time consuming, complex and must be conducted at a well-equipped laboratory. In order to
provide a diagnostic tool for paratuberculosis at point of need, here we described a rapid extraction
protocol (MAP DNA SpeedXtract) based on magnetic bead. The destruction of the MAP cell wall
in the SpeedXtract depends on the combination of physical disruption and heat in the presence of
a lysis bu↵er. The magnetic beads capture the cell debris and most contaminants and then leave
the nucleic acid free in the supernatant [13–15]. Therefore, the SpeedXtract was named a reverse
purification method.
2. Materials and Methods
2.1. Sample Origin
The study included 45 bovine stool samples which were collected during routine veterinary
examination in Division of Microbiology and Animal Hygiene, Goettingen. All samples were taken
under consideration of the German codex “Gute Veterinärmedizinische Praxis”.
2.2. Development of MAP SpeedXtract Protocol
In order to establish a rapid point of need nucleic acid extraction method, 11 di↵erent pre-treatment
steps (Table 1) were combined with a basic SpeedXtract procedure. All methods were evaluated using
bovine faecal sample containing intact MAP particles.
The basic SpeedXtract (QIAgen, Hilden, Germany) was performed as follows: 500 µL of lysis
bu↵er (Bu↵er SL) and 60 µL of magnetic beads were added to the faecal samples. The mix was vortexed
for 10 s and incubated at 95  C. Every two minutes, the tube was taken out from the heat block and
vortexed. Following 15 min of incubation time, the tube was placed on a magnetic rack. After two
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2.3. RPA Assay
The RPA assay was conducted as published previously [6]. Briefly, 5 µL of the diluted
supernatant, 29.5 µL Rehydration Bu↵er, 6.7 µL molecular biology water, 2.1 µL of 10 µM of
both Forward Primer (50-CGTGGACGCCGGTAAGGCCGACCATTACTGCATGG-30) and Reverse
Primer (50-CGCCGCAATCAACTCCAGCAGCGCGGCCTC-30), 0.6 µL of the 10 µM of the exo
probe (50-ACGCCGGTAAGGCCGACCATTACTGCATGGT BHQ1-dt, Tetrahydrofuran and Fam-dT
TAACGACGACGCGCA-PH-30) and 2.5 µL of 14 mM Mg acetate were added to a freeze-dried reaction
pellet ordered from TwistDx (TwistDx Ltd., Cambridge, UK). The tube was incubated at 42  C for 15
min. The fluorescence signals were recorded every 30 s. The RPA threshold time was calculated using
the first derivative value obtained by the Studio Software (Qiagen Lake Constance, Stockach, Germany).
2.4. Clinical Sensitivity and Specificity
The clinical performance of the selected MAP DNA SpeedXtract protocol in combination with
the MAP RPA was validated using 100 mg of each of the 45 clinical samples. From the same
samples, DNA was extracted using the standard laboratory protocol (QIAamp DNA Blood Mini
Kit, (QIAgen GmbH, Hilden, Germany)) and was screened with a well-established IS900 real-time
PCR (FP: 50-TACCGCGGCGAAGGCAAGAC-30; RP: 50-CGGAACGTCGGCTGGTCAGG-30, probe:
50-FAM-ATGACATCGCAGTCGAGCTG-BHQ-1-30), as previously described [12].
3. Results
Eleven di↵erent pre-treatment steps in combination with a basic SpeedXtract procedure were tested
to establish a rapid point of need nucleic acid extraction method. The performance of the extraction
protocols was compared with the standard laboratory extraction method using a MAP-positive faecal
sample. The results are summarized in Table 1 and Supplementary Figure S1. Protocol #10 was selected
as minimal pre-treatment steps and equipment were required (Figure 1), in addition to the production
of a comparable result to the standard laboratory procedure (Figure 2). The whole procedure conducted
in protocol #10 is illustrated in Figure 1 and Supplementary File S1.Diagnosti s 2019, 9, 36 5 of 11 
 
 
Figure 1. Workflow of the rapid point of need Mycobacterium avium subspecies paratuberculosis (MAP) 
extraction protocol. The procedure combines bead beating together with the basic SpeedXtract 
method. It represents protocol number 10 in Table 1. 
Figure 2. RPA results of DNA extracted either by using the QIAamp DNA Mini Blood Kit (blue) and 
the MAP SpeedXtract protocol (purple). Neg is negative. 
Each of the 45 faecal samples were mixed well and divided into two parts (100 mg each). DNA 
was extracted from the first portion with the QIAamp DNA Blood Mini Kit and MAP DNA was 
detected with real-time PCR, while for the other portion, SpeedXtract and MAP RPA were applied. 
Comparing the results of both protocols revealed that 23/45 tested samples were negative by both 
methods. Twenty-two samples tested positive in the real-time PCR, while 20 were positive in the 
MAP RPA assay. No correlation between the threshold time of the RPA and cycle threshold of the 

































Figure 1. Workflow of the rapid point of need Mycobacterium avium subspecies paratuberculosis (MAP)
extraction protocol. The procedure combines bead beating together with the basic SpeedXtract method.
It represents protocol number 10 in Table 1.
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Figure 2. RPA results of DNA extract d either by using the QIAamp ini Blo d Kit (blue) and
the MAP SpeedXtrac pr tocol ( urple). Neg is negative.
Each of the 45 faecal samples were mixed well and divided into two parts (100 mg each). DNA
was extracted from the first portion with the QIAamp DNA Blood Mini Kit and MAP DNA was
detected with real-time PCR, while for the other portion, SpeedXtract and MAP RPA were applied.
Comparing the results of both protocols revealed that 23/45 tested samples were negative by both
methods. Twenty-two samples tested positive in the real-time PCR, while 20 were positive in the MAP
RPA assay. No correlation between the threshold time of the RPA and cycle threshold of the real-time
PCR was found (Figure 3).Diagnostics 2019, 9, 36 6 of 11 
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method, based on magnetic bead reverse purification and RPA, respectively. The complete procedure 
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specificity and 90.9 % sensitivity in comparison to the standard laboratory methods. 
Many protocols for the extraction of MAP DNA have been developed in the past years (Table 2). 
All tested methods have showed outstanding clinical sensitivities, however long preparation time 
and several pipetting steps were necessary. This increases the risk of contamination, especially while 
working with bovine faecal samples at point of need. Leite et al. applied a rapid MAP extraction 
procedure [16], nevertheless, a high-speed centrifuge is needed and most centrifuges fail to work 
under field conditions [17]. Using the SpeedXtract removes the need of a high-speed centrifuge. In 
addition, the time from sample receiving to result including MAP RPA assay and handling is 45 min 
and only three pipetting steps are needed. The reverse purification technique, i.e., only inhibitors 
binding to the magnetic beads, can increase the yield of DNA since no multiple washing and elution 
steps are required. An additional benefit is that all reagents of the SpeedXtract Nucleic Acid Kit as 
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Mondal et al. and Gunaratna et al. applied the basic SpeedXtract Nucleic Acid Kit for the 
isolation of the Leishmania donovania DNA from a blood sample and skin biopsies, respectively [13,15].  
Using the SpeedXtract virus kits, Weidmann et al. and Schlottau et al. isolated the Ebola and Rabies 
viral RNA from blood/swab samples and brain tissue, respectively [18,19]. Here is the first report on 
deploying the SpeedXtract for bacterial DNA isolation. 
MAP colonies from middlebrook 7H11 agar plates have a high content of free DNA [20]. Therefore, 
spiking negative samples with a certain number of bacteria in order to determine the potency of the 
SpeedXtract was not useful. Thus, we relied on field samples to determine the clinical feasibility of 
the developed protocol. 
The supernatant of the SpeedXtract did inhibit the real-time PCR as its colour stayed dark 
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including real-time PCR, however this is not the case with the RPA as the RPA is more resistant to an 
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Figure 3. Results of clinical samples screened with both the MAP DNA SpeedXtract/MAP RPA protocol
and the QIAamp DNA Blood Mini Kit/real-time Polymerase Chain Reaction (PCR) protocol. No
correlation was found as the RPA assay was very fast, even with samples of high CT value. TT is
threshold time; CT is cycle threshold.
4. Discussion
In this study, we developed a fast and easy to handle MAP DNA extraction and detection method,
based on magnetic bead reverse purification and RPA, respectively. The complete procedure was
optimized for use in the mobile suitcase laboratory [15]. The protocol reached the same clinical
specificity and 90.9 % sensitivity in comparison to the standard laboratory methods.
Many protocols for the extraction of MAP DNA have been developed in the past years (Table 2).
All tested methods have showed outstanding clinical sensitivities, however long preparation time
and several pipetting steps were necessary. This increases the risk of contamination, especially while
22
Diagnostics 2019, 9, 36 6 of 9
working with bovine faecal samples at point of need. Leite et al. applied a rapid MAP extraction
procedure [16], nevertheless, a high-speed centrifuge is needed and most centrifuges fail to work under
field conditions [17]. Using the SpeedXtract removes the need of a high-speed centrifuge. In addition,
the time from sample receiving to result including MAP RPA assay and handling is 45 min and only
three pipetting steps are needed. The reverse purification technique, i.e., only inhibitors binding to
the magnetic beads, can increase the yield of DNA since no multiple washing and elution steps are
required. An additional benefit is that all reagents of the SpeedXtract Nucleic Acid Kit as well as the
RPA are stable long term at room temperature, i.e., cold chain independent.
Mondal et al. and Gunaratna et al. applied the basic SpeedXtract Nucleic Acid Kit for the isolation
of the Leishmania donovania DNA from a blood sample and skin biopsies, respectively [13,15]. Using the
SpeedXtract virus kits, Weidmann et al. and Schlottau et al. isolated the Ebola and Rabies viral RNA
from blood/swab samples and brain tissue, respectively [18,19]. Here is the first report on deploying
the SpeedXtract for bacterial DNA isolation.
MAP colonies from middlebrook 7H11 agar plates have a high content of free DNA [20]. Therefore,
spiking negative samples with a certain number of bacteria in order to determine the potency of the
SpeedXtract was not useful. Thus, we relied on field samples to determine the clinical feasibility of the
developed protocol.
The supernatant of the SpeedXtract did inhibit the real-time PCR as its colour stayed dark brown.
In other words, the DNA extracted by SpeedXtract is not suitable for any applications including
real-time PCR, however this is not the case with the RPA as the RPA is more resistant to an inhibitor
than the real-time PCR [6].
The most di cult aspect in the DNA extraction is the lipophilic compounds of the MAP cell wall
and clusters which resist acid or alkaline lysis bu↵ers [21]. Bead beating is shown to increase the
quality and quantity of yielded DNA [22]. The beads disrupt the cell wall and clusters by causing
turbulences and mechanical shearing [23]. Therefore, a bead beating step was implemented in the
protocol. As shown in Table 1, implementing treatment with ultrasonic or proteinase or protease gave
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5. Conclusions
In conclusion, we developed a rapid and sensitive protocol for the extraction of MAP DNA. The
uncomplicated setup as well as the minimal technical demand of the SpeedXtract and RPA methods
enables implementation in a mobile suitcase laboratory [15]. This eases the detection of MAP shedders
within the herd directly at the point of need.
Supplementary Materials: The following are available online at http://www.mdpi.com/2075-4418/9/2/36/s1,
File S1: MAP SpeedXtract Protocol #10; Figure S1: (A) RPA results of DNA extracted either by the QIAamp DNA
Mini Blood Kit (blue) or the MAP SpeedXtract protocol with use of Proteinase K (purple) and without (pink).
(B) Performance of the DNA extraction protocols #7 to #10.
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Point of need diagnostics
Zika virus
A B S T R A C T
Background: Outbreaks of fever of unknown origin start with nonspecific symptoms and case definition is only
slowly developed and adapted, therefore, identifying the causative agent is crucial to ensure suitable treatment
and control measures. As an alternative method for Polymerase Chain Reaction in molecular diagnostics diag-
nostic, metagenomics can be applied to identify the pathogen responsible for the outbreak through sequencing
all nucleic acids present in a sample extract. Sequencing data obtained can identify new or variants of known
agents.
Objectives: To develop a rapid and field applicable protocol to allow the identification of the causative agent of
an outbreak.
Study design: We explored a sequencing protocol relying on multiple displacement isothermal amplification and
nanopore sequencing in order to allow the identification of the causative agent in a sample. To develop the
procedure, a mock sample consisting of supernatant from Zika virus tissue culture was used.
Results: The procedure took under seven hours including sample preparation and data analysis using an offline
BLAST search. In total, 63,678 sequence files covering around 10,000 bases were extracted. BLAST search re-
vealed the presence of Zika virus.
Conclusion: In conclusion, the protocol has potential for point of need sequencing to identify RNA viruses. The
whole procedure was operated in a suitcase laboratory. However, the procedure is cooling chain dependent and
the cost per sequencing run is still high.
1. Background
Identifying the causative agent implicated in an outbreak is crucial
for selecting the suitable treatment and/or control measures [1]. For
example, around 25 pathogens can cause influenza like symptoms in
the acute phase [2] and up to 20 pathogens have to be considered for
diarrhoea [3].
For direct detection of pathogens, polymerase chain reaction (PCR)
is a widely used and well-established test for molecular diagnostics.
Since specificity of PCR oligonucleotides depends on known sequences
of specific target genes, false negative PCR result might be obtained due
to a mismatching sequence of a novel variant of a known pathogen or
because of a new emerging infectious agent. An alternative promising
technology is diagnostic metagenomics, which can be applied to iden-
tify the pathogen responsible for the outbreak through sequencing of all
nucleic acids in a sample allowing generic detection not limited by
specific oligonucleotide design. Additionally, diagnostic metagenomics
data sets on detected infectious agents can be used for phylogenetic and
molecular epidemiological analysis to provide insights into strain and
origin of the agent. This information can be crucial for organization and
distribution of resources during the outbreak control [4,5].
There are many high-throughput sequencing technologies available
such as sequencing by synthesis, using HiSeq and MiSeq platform
(Illumina, USA). These devices have a high data output, an error rate
below 2% and the possibility to sequence several samples in parallel
[6]. Nevertheless, there is a high logistic demand through weight, size
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and costs of the equipment as well as expensive service contracts.
Furthermore, cumbersome and long sample and library preparation
protocols are necessary in order to generate results [6,7]. In contrast,
nanopore sequencing technology (Oxford Nanopore Technology, UK)
uses a pore-protein embedded in a membrane to identify individual
nucleotides by the unique change in electrical conductivity as a DNA
molecule passes through the nanopore protein. Recently, Oxford Na-
nopore Technology developed a pocket sized (10.5+ 3.5+2.5 cm)
sequencing device (MinION), which has the potential to be applied in
the field or rural areas. A flow cell containing the required nanopores is
inserted into the MinION in order to conduct the sequencing run. The
MinION device operates at a constant sequencing temperature (34 °C)
and translates the measured changes in current to a real-time nucleo-
tide sequence via USB connection to a laptop [7–10].
2. Objective
Here we describe the establishment of a protocol for rapid identi-
fication of RNA viruses combining random isothermal amplification
and nanopore sequencing using Zika virus (ZIKV) as model virus. The
protocol was performed in a mobile suitcase laboratory (Fig. 1) in order




The Zika virus strain HD78788 was isolated in 1991 in Senegal
during surveillance. Viral stocks were prepared by inoculating viral
strains into Aedes pseudoscutellaris clone 61 (AP61) monolayer cells.
Viral infection was confirmed by an indirect immunofluorescence assay
using specific hyper-immune mouse ascitic fluid as described previously
[12].
3.2. Sample preparation
Zika virus (ZIKV) RNA was extracted from cell culture supernatant
using the QIAamp Viral RNA Mini Kit (QIAGEN Hilden, Germany)
following the manufacturer’s instructions. The RNA quantity was
measured by NanoDrop ND-1000 spectrometer (Thermo Scientific,
Waltham, MA, USA). For elimination of genomic DNA and reverse
transcription, the QuantiTect Reverse Transcription Kit (QIAGEN
Hilden, Germany) was employed using a prolonged incubation time
(25min) for the reverse transcription step. Second strand cDNA
Synthesis was performed with the NEBNext mRNA Second Strand
Synthesis Module (New England Biolabs, Ipswich, MA, USA). The
double-stranded cDNA (ds-cDNA) was purified with the 1.8X Agencourt
AMPure XP Beads Kit (Beckman Coulter, Brea, CA, USA), eluted in
55 μL nuclease-free water and quantified (NanoDrop ND-1000). To
fragment and increase the amount of DNA, random amplification was
done using the REPLI-g UltraFast Mini Kit (QIAGEN Hilden, Germany).
Briefly, 1 μL of ds-cDNA, containing at least 10 ng, was incubated with
1 μL denaturation buffer at room temperature for three min. The reac-
tion was terminated by addition of 2 μL neutralization buffer. The de-
natured ds-cDNA was mixed with 16 μL of the master mix containing
15 μL REPLI-g UltraFalst reaction buffer and 1 μL REPLI-g UltraFast
DNA polymerase and incubated at 30 °C for 90min. The reaction mix
was heated to 65 °C for 3min to inactivate the reaction enzymes. Then,
the DNA was purified with the 1.8X Agencourt AMPure XP Beads Kit,
eluted in 30 μL nuclease free water and quantified (NanoDrop ND-
1000).
3.3. Library preparation and sequencing
For library preparation, the protocol for amplicon sequencing, SQK-
NSK007, was used as recommended by Oxford Nanopore Technology.
Briefly, 45 μL containing at least 1 μg ds-cDNA were used for end-re-
pairing and dA-tailing using the NEBNext Ultra II end-repair / dA-
tailing module. The end-repaired DNA was purified with the 1.8X
Agencourt AMPure XP Beads Kit and eluted in 31 μL nuclease free
water. DNA recovery aim was at least 700 ng/μL. Adapter ligation and
Fig. 1. The content of the mobile suitcase laboratory for sequencing.
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tethering was carried out with the NEB Blunt/TA Ligase Master Mix.
The DNA was purified using the Dynabeads® MyOne™ Streptavidin C1
Kit (Thermo Fisher Scientific, Waltham, MA, USA) and dissolved in
25 μL of elution buffer (Oxford Nanopore Technology, Oxford, UK). Six
microliters of the adapted and tethered DNA was mixed with 31.5 μL
nuclease free water and 37.5 μL of running buffer FM1 (Oxford
Nanopore Technology, Oxford, UK) and then loaded into the R9 flow
cell in the MinION device.
3.4. Data processing
The MinION device generates raw data in HDF5 format. The files
were transformed to FASTQ format with poretools toolkit v0.6.0 [13].
Duplicate reads were deleted and the remaining sequences were used
for a local BLAST search using Geneious v9.1.6 (Biomatters Ltd.,
Auckland, New Zealand). The custom BLAST database was built from
all 7246 virus genome assemblies available on the NCBI databases
(accessed the 2017-05-01). Contigs were aligned to ZIKV genome (ac-
cession KF383115.1) strain via “Map to Reference” option in GENEI-
OUS. A standard i5 Laptop using Windows 7 was used for all steps.
4. Results
The described procedure took less than seven hours (∼400min) as
shown in Table 1. In total, 63,678 sequences were extracted and
transformed to FASTQ format. After running a local BLAST against a
viral genome database (e-value threshold: 10−10), ZIKV sequences were
identified in approximately 4% of the reads. The complete original
ZIKV sequence (GenBank accession number: KF383115.1) was re-
covered with 2454 reads with an average read length of 685. The
maximum coverage rate was 585 reads and the minimum was 36 reads
(Std. Dev.: 122.6). Pairwise identity in BLAST analysis was 67.4%.
Additionally, a total of 411 correct ZIKV reads were found in the
HDF5 failed call files. When included in the assembly they matched
correctly to the respective ZIKV sequence (Fig. 2).
A total of 2043 pass and 411 fail reads were aligned to the ZIKV
sequence (GenBank accession number: KF383115). The pass reads
showed a better coverage rate (Max.: 190, Min.: 21, Std. Dev.: 40, Fig. 2
panel A), while the fail reads has a better sequence identity to the re-
ference strain (Fig. 2 panel B).
5. Discussion
Identifying the causative agent of an outbreak using sequencing
instead of other molecular techniques like PCR could have a high im-
pact on selecting and implementing the right patient management and
control measures.
The most widespread sequencing device is the MiSeq, as Illumina`s
smallest device, which has nevertheless a size of 68.6+52.3+56.5 cm
and a weight of approximately 57 kg. Moreover, it has a higher data
output (up to 15 Giga bases) in comparison to the MinION (10 Giga
bases). Nevertheless, read length by MiSeq is limited to around 300 bp
and a maximum of 22–25 million reads can be produced in a run time
between 4 h and 56 h [14,15]. In contrast, the MinION has through its
nanopore technology no limit in read length and number. Moreover,
reads are generated in 20–40min and data are easily accessible on
laptop.
We have found that 1/5 of the correct ZIKV reads were classified as
failed. MinKNOW platform categorises the reads into pass and fail reads
by neuronal network computing assessing definite conductivity readout
events at the pore exit for 5–6 mers. This complicated sequence defi-
nition needs quality scoring to decide on the statistical trustworthiness
of the sequencing result. Fails are defined through the following ap-
proach. Initially base calling (1D base calling) of template and com-
plement reads is performed separately. If the resulting sequence length
ratio is between 0.5–2.0, all sequences are stacked together for 2D base
calling. If resultant 2D sequences are assessed with a mean Q-score ≤9
they are sorted into a fail sequence file [16].
Short Illumina device reads have a 0.1% non-random error rate,
which means an error at one site can still dominate the base calling
process. The MinION reads have a 10% error rate but sites are dis-
tributed at random throughout the sequence which is compensated for
by base calling and which therefore do not dominate at one site redu-
cing the overall error rate in comparison to Illumina reads [17]. Our
results suggest that the analysis algorithm and the Q-score need to be
optimised for viral RNA sequences. At this current development stage,
therefore, a recommended assembly approach would be first to use all
pass reads to identify the infectious agent. To improve the result, the
fail reads can be included in a 2nd step.
The MinION was successfully used in the Ebola virus outbreak in
Guinea [9] and during the Zika virus outbreak in Brazil [18]. In both
cases, specific PCR fragment sequencing strategies were used. RT-PCR
assays were applied to reverse transcribe RNA and create multiple
fragments to increase the sequencing efficacy [9,19]. This strategy
limits sequencing output to targeted agents, which is ideal for mole-
cular epidemiological analysis. The use of PCR leads to logistic issues
due to heavy devices and requirement of a cold chain for the reagents.
In Brazil, this was solved by transporting the whole laboratory in a
caravan. The generic sequencing approach described here is intended
for diagnostic identification of unknown infectious agents. It uses only
random isothermal steps throughout the procedure and PCR cycling is
not required, which avoids the use of a thermal cycler.
We have already shown that isothermal amplification can be easily
implemented in a mobile suitcase laboratory [11,20,21] and we suc-
cessfully adapted this concept for the workflow needed for library
preparation for the MinION sequencing procedure (Fig. 1). The suit-
case, contains all materials and reagents needed for sequencing in one
box of 56.0+45.5+26.5 cm in size and less than 23 kg in weight.
All steps of data collection and analysis were performed offline
using MinKNOW and Geneious. This is a major improvement since
during the Ebola outbreak base calling for MinION datasets was only
possible through cloud computing which needed internet capacity often
not available locally [9]. The simple structure and clear layout of these
analysis programmes makes it easy for users without bioinformatic
background to obtain basic information about origin and phylogeny of
the sequenced target. Therefore, a bioinformatician is not necessarily
Table 1
Sequencing Workflow.
Diagnostic procedure diagnostic tools (kit, device or software) required time (min)
RNA extraction QIAamp Viral RNA Mini Kit 30
DNA digestion and reverse transcription QuantiTect Reverse Transcription Kit 35
second strand cDNA synthesis NEBNext mRNA Second Strand Synthesis Module 90
random isothermal amplification REPLI-g UltraFast Mini Kit 120
library preparation Nanopore sequencing kits: SQK-NSK007 70
Sequencing MinION device, R9 flow cell and MinKNOW 20
data analysis and BLAST search PORETOOLS and Geneious 9.1.6 35
Total 400
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required for analysis of the datasets obtained in the field.
Currently, the following challenges have to be solved. In our hands,
the sequencing reagents can be kept at 25 °C for one day without any
changes in their efficacy (confirmed by Oxford Nanopore Technologies,
UK). However, for long-term storage a −20 °C freezer is still required.
Moreover, the price per sequencing run is very high (around $1500), as
one flow cell costs between $500 and $900 depending on the amount of
ordered flow cells. In addition, the shelf life of the flow cells is around 8
weeks at 4 °C. One of the biggest drawbacks is that the manufacturer is
progressively changing the reagents and flow cells so that it is difficult
to match biochemistry to flow cells.
The goal of this study was to establish a protocol for pathogen
identification during an outbreak field investigation. In principle, this
seems possible in a suitcase laboratory setup. The next steps will be to
identify cold chain independent reagents.
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A B S T R A C T
Foot-and-mouth disease virus (FMDV), belonging to the family of Picornaviridae, infects mostly cloven-hoofed
animals and leads to huge economic losses. Since there is no cross-protection between the seven serotypes of
FMDV, effective vaccination relies on the knowledge of the serotype causing the outbreak. The most common
methods of serotyping are antigen ELISAs and amplification-based sequencing. Serotype-specific PCR methods
exist but have limitations due to emerging mutants within serotypes. Sequencing is a promising technology, but
currently suffers from cumbersome procedures and long turnaround times. In this study, we have established a
novel sequencing protocol relying on nanopore sequencing and offline BLAST search. The procedure was
completed in 5 h including RNA extraction, reverse transcription, second-strand synthesis, barcoding, sequen-
cing and data analysis, which did not require a bioinformatician. In total, 12,193 sequence files were obtained.
The offline BLAST search to the P1 region revealed the most successful categorization of the seven FMDV ser-
otypes (specificity: 98.3%) over whole genome (24.8%), P2 (23.6%) and P3 (21.4%). In conclusion, our protocol
enables rapid and reliable FMDV serotyping. The whole procedure can be conducted with a mobile suitcase
laboratory, which is easy to use at the point of need in endemic countries.
1. Introduction
Foot-and-mouth disease virus (FMDV) is a highly infectious positive
single-stranded RNA virus belonging to the family of Picornaviridae.
The virus affects mainly cloven-hoofed animals causing huge economic
losses including high mortality in young stock, reduced herd fertility
and productivity, trade restrictions as well as high cost for control
programs. FMDV has seven serotypes (SAT1-3, Asia-1, A, O and C).
Vaccines are available, but there is no cross-protection between the
serotypes and tremendous variability within them. Thus, identifying the
serotype and strain is crucial to select an appropriate vaccine to confine
outbreaks (Knight-Jones and Rushton, 2013; Tekleghiorghis et al.,
2014). Antigen ELISA with serotype-specific polyclonal sera is the most
common method of serotyping FMDV (Roeder and Le Blanc Smith,
1987). However, the ELISA has limited sensitivity and is prone to cross-
reactions between serotypes. Type-specific RT-PCRs targeting the VP1-
encoding genome region are also applied for serotyping, both as con-
ventional and real-time PCR is highly sensitive and specific, but most
typing assays are tailored to a pool of viruses circulating in a defined
region and may not be able to identify emerging strains or new viruses
of unknown origin that are introduced into free areas (Bachanek-
Bankowska et al., 2016). Another promising way of serotyping is se-
quencing of the FMDV genome, which also gives more insight into the
virus evolution and allows tracing the origin and spread of an outbreak.
However, many current VP1 sequencing protocols are lengthy and
cumbersome procedures including two amplification steps, in addition
to the need of expensive equipment and reagents (Dill et al., 2017;
Knowles et al., 2016; Longjam et al., 2011; Soltan et al., 2017).
In this study, we established for the first time a rapid sequencing
protocol for FMDV serotyping using a nanopore sequencing method
operated in a mobile suitcase laboratory.
2. Material and methods
2.1. Viruses
The FMDV isolates A22 IRQ 24/64, O1 Manisa TUR/69, C1 Noville
SWI/65, Asia-1 Shamir ISR/89, SAT1 ZIM 25/89, SAT2 ZIM 11/91 and
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SAT3 ZIM 4/81 were selected from archival stocks at the Friedrich-
Loeffler-Institut (FLI), Germany.
2.2. Sample preparation and RNA extraction
Fresh cultures of all isolates were grown separately in monolayers of
BHK-21 cells (RIE 164, Collection of Cell Lines in Veterinary Medicine,
FLI). Infected cells were incubated in a closed system at 37 °C until full
cytopathic effect was visible. After freezing and thawing, the super-
natant of the seven samples was clarified of cell debris by centrifugation
for 10min at 3200 × g at 4 °C. Virus was pelleted through a 30% (wt/
vol) sucrose cushion in 40mM sodium phosphate buffer (pH 7.6) with
100mM sodium chloride (buffer P as in (Gullberg et al., 2013)) by
centrifugation at 125,755 × g in a SW32Ti rotor (Beckman Coulter,
Optima 170 LE-70) for 2 h 50min at 7 °C. Pellets were resuspended in
140 μL buffer P. FMDV RNA of the individual serotypes was extracted
using the RNeasy® Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. RNA content was determined with a
spectrophotometer (NanoDrop 2000c, Thermo Fisher Scientific) by re-
peated measurements of absorption at 260 nm.
Under field conditions, where no centrifuge is available, the RNA
extraction can be performed directly from vesicular material with the
Dynabeads SILANE Viral Nucleic Acid kit (Invitrogen, Darmstadt,
Germany) as described previously (Abd El Wahed et al., 2013).
2.3. Library preparation
The library preparation was carried out in the mobile suitcase la-
boratory using a direct cDNA native barcoding protocol (Fig. 1; the full
procedure is shown in additional file 1). Firstly, reverse transcription
and strand switching was performed with 250 ng of RNA using the In
vitro SuperScript IV VILO Master Mix (ThermoFisher Scientific, Wal-
tham, MA, USA) with the VNP primer targeting the poly-A tail of FMDV
RNA (5′-phosphate-ACTTG CCTGT CGCTC TATCT TCTTT TTTTT
TTTTT TTTTT TTVN-3′) and strand-switching primer (5′-TTTCT
GTTGG TGCTG ATATT GCTGC CATTA CGGCC-mGmGmG with 2' O-
methyl RNA bases-3′), respectively. These primers were suggested by
Oxford Nanopore Technologies; for details about their function, please
refer to (Zhu et al., 2001). Secondly, 2nd strand synthesis was con-
ducted using the LongAmp Taq Master Mix (New England Biolabs,
Ipswich, MA, USA) and PR2 primer (5′-TTTCT GTTGG TGCTG ATATT
GC-3′). Thirdly, end-repairing was performed using the NEBNext Ultra
II end-repair/dA-tailing module (New England Biolabs). Barcoding was
carried out with the NEB Blunt/TA Ligase Master Mix (New England
Biolabs) and Native Barcoding Kit 1D (NBD103, Oxford Nanopore
Technologies, Oxford, UK) as follows: Barcodes 1, SAT1; 2, SAT2; 3,
SAT3; 4, Asia-1; 5, A; 6, O; 7, C. After barcoding, the samples were
pooled together. Fourthly, ligation of sequencing adaptor and tether
attachment was done using the SQK-DCS108 sequencing kit (Oxford
Nanopore) and NEB Blunt/TA Ligase Master Mix. Finally, the pre-
paration was mixed with running buffer FM1 and Library Loading
Beads Buffer (Oxford Nanopore) and loaded into an R9.4 flow cell fixed
on the top of the MinION device (Oxford Nanopore).
2.4. Data processing
The sequencing run was performed in a MinION (Oxford Nanopore)
within 20min. The data was automatically saved in FAST5 format on
Fig. 1. Work flow and the required equipment for the serotyping of FMDV.
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the laptop via the MinKnow Software (Oxford Nanopore). The sequence
files were automatically transferred to FASTQ format and categorized
into barcodes using ALBACORE 2.0.1 (Oxford Nanopore). Duplicated
reads and sequences less than 300 and more than 9000 nucleotides
were deleted using GENEIOUS v9.1.6 (Biomatters Ltd., Auckland, New
Zealand). Thereafter, sequences were aligned to offline local BLAST
databases encompassing either P1, P2, P3 or the whole FMDV genome
(for full sequence and accession numbers, please see additional file 2).
The offline database was created ahead of time according to the pro-
cedure in the GENEIOUS manual. Local BLAST search was also per-
formed using GENEIOUS applying the MEGABLAST algorithm and
showing results as Query-centric alignment only. A maximum of 1000
hits per read was allowed with an E-value of 1e-100. Decision on the
serotype was made based on the total number of possible GenBank data
hits aligned to the nanopore sequence data. In order to determine the
specificity of using the offline database of either the whole FMDV
genome or particular gene region for serotyping, the number of hits
from a particular serotype aligned correctly to sequence reads was di-
vided by the total number of hits of all serotypes placed under the same
barcode. A hit is one FMDV sequence with a distinct GenBank accession
number.
3. Results
In total, 12,193 sequence files were generated and processed to
FASTQ, from which 7372 could pass our sequence filtration.
Categorization of the reads into the various barcodes is shown in Fig. 2.
BLAST search revealed between 14.3 and 32.5 percent of the reads as
FMDV sequences. Serotyping using BLAST searches to the whole
genome as well as to sequences of the P2 and P3 region of FMDV re-
vealed a very poor specificity, 24.8, 23.6 and 21.4%, respectively. In
contrast, applying the P1 database for alignment to the reads via
MEGABLAST yielded the highest specificity (98.3%).
4. Discussion
We have developed a rapid sequencing method for serotyping of
FMDV. Direct cDNA sequencing using a MinION device was combined
with an offline local BLAST search in order to allow point-of-need
FMDV serotyping. The whole protocol was carried out within five
hours. Moreover, a bioinformatic background is not required due to the
user-friendly interface of GENEIOUS as all steps of data processing are
easy to execute and results are presented in a clear way as query-centric
alignment. In addition, no highly complicated analysis procedure is
needed as the nanopore data was used for identifying the serotype, not
for whole genome assembly, which is more convoluted.
In this study, we applied a local BLAST search to align the obtained
reads to FMDV sequences stored in GenBank. By establishment of an
offline local data-calling algorithm, we decreased the time to result and
overcame the need of a stable and powerful internet connection, which
is usually absent in the areas most affected by FMD. The FMDV open
reading frame consists of four functional regions (L, P1-3). P1 encodes
the structural proteins of the virus, while L, P2 and P3 contain non-
structural proteins that play an important role in virulence, viral re-
plication and virus-host interaction (Gao et al., 2016). It is not sur-
prising that the P1 region worked best for serotyping because i) P2 and
P3 are more conserved between the different serotypes ii) the NCBI
database did not contain enough sequences of the P2 and P3 regions to
cover all variants of the serotypes (Carrillo et al., 2005). Co-infection
with different serotypes can be efficiently determined via the calcula-
tion of the number of hits allocated to each serotype.
Using sequencing overcomes the problem of variability in the
genome as viruses from all serotypes can be detected independent of the
geographical region or virus pool.
Previously published sequencing protocols rely mainly on sequen-
cing by synthesis using either Sanger or Illumina sequencing (Knowles
et al., 2016; Logan et al., 2014). These approaches are cost-effective and
yield accurate sequences with high throughput. However, both methods
are not field applicable, due to the need of expensive and complex
devices, and have time-consuming protocols. Additionally, Illumina
sequencing requires a bioinformatic background for data analysis. In
contrast, the nanopore sequencing produced results in a very short time
and the whole procedure can be performed in a mobile suitcase la-
boratory (Abd El Wahed et al., 2015), with no need for sophisticated
infrastructure or laboratory capacities. This enables serotyping directly
at the site of an outbreak in low-resource settings. In FMDV-free
countries, native samples from suspect animals must be handled with
greater care, but after they have been treated with a lysis buffer, the
downstream analysis can be safely performed under BSL-2 conditions.
A −20 °C freezer is still needed for long-term storage of sequencing
reagents. Fortunately, the sequencing kits and the flow cells can be kept
at room temperature for one day, which is more than enough to per-
form the experiment. One of the big limitations of the technology is the
cost per one sequencing run for seven samples (€2300) and another
€8500 is needed as a starting cost for the suitcase laboratory.
Rapid sequencing of RNA viruses was established before by others
(Batovska et al., 2017) employing the SuperScript III First-Strand
Synthesis System (ThermoFisher Scientific, Waltham, MA, USA) and
random hexamer primers for cDNA synthesis along with the SQK-
NSK007 kit (Oxford Nanopore Technologies, Oxford, UK) for library
preparation. By contrast, in our study we have used the SuperScript IV
VILO kit, which produces higher quality cDNA in less time (10min). In
addition, the application of a poly-T primer binding to the poly-A tail of
the FMDV RNA has allowed the synthesis of a long cDNA strand instead
of multiple cDNA fragments in the case of random hexamer primers.
Furthermore, the SQK-NSK007 kit is designed for the sequencing of a
single sample, while the SQK-DCS 108 kit allowed us to sequence seven
samples simultaneously in the same run.
Generally, various sequencing methods have a limit of detection at
104 DNA molecules per tested sample (Liu et al., 2012). In clinical cases
Fig. 2. Flow chart of analysing the sequence data using offline BLAST search.
The lower graph shows the success rate of BLASTing the reads to the right
FMDV serotype.
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of FMDV, the viral load in the vesicular lesions is high (≥1011 genome
copies/g) and in the preclinical phase it ranges from 105.1 to 109.8
genome copy/g (Pharo, 2002; Stenfeldt et al., 2015). In carrier animals,
the viral load in probang samples is low: 103.5-105.2/ml (Stenfeldt et al.,
2016). However, the amount of highly purified RNA needed for se-
quencing can easily be obtained either directly or by a nucleic acid
concentration method.
5. Conclusions
In conclusion, we have developed a fast and reliable method for
sequence-based serotyping of FMDV. The whole procedure can be easily
implemented in a regular laboratory workflow or with a mobile suitcase
laboratory in a low-resource setting. The next points to address will be
the decrease of pipetting steps and the switch to lyophilized reagents,
which are stable at ambient temperature.
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Diagnosing Zika virus infection 
against a background of other 
flaviviruses: Studies in high 
resolution serological analysis
Sören Hansen1, Sven-Kevin Hotop2,3, Oumar Faye4, Oumar Ndiaye4, Susanne Böhlken-
Fascher1, Rodrigo Pessôa5, Frank Hufert6, Christiane Stahl-Hennig7, Ronald Frank8, 
Claus-Peter Czerny1, Jonas Schmidt-Chanasit9,10, Sabri S. Sanabani5, Amadou A. Sall4, 
Matthias Niedrig11, Mark Brönstrup  2,3, Hans-Joachim Fritz12 & Ahmed Abd El Wahed1
Zika virus (ZIKV) is a mosquito-borne flavivirus. Homologous proteins of different flaviviruses display 
high degrees of sequence identity, especially within subgroups. This leads to extensive immunological 
cross-reactivity and corresponding problems for developing a ZIKV-specific serological assay. In this 
study, peptide microarrays were employed to identify individual ZIKV antibody targets with promise 
in differential diagnosis. A total of 1643 overlapping oligopeptides were synthesized and printed onto 
glass slides. Together, they encompass the full amino acid sequences of ZIKV proteomes of African, 
Brazilian, USA, and French Polynesian origins. The resulting ZIKV scanning microarray chips were used 
to screen three pools of sera from recent Zika outbreaks in Senegal and Cape Verde, in Brazil, and from 
overseas travelers returning to the EU. Together with a mixed pool of well characterized, archived sera 
of patients suffering from infections by dengue, yellow fever, tick-borne encephalitis, and West Nile 
viruses, a total of 42 sera went into the study. Sixty-eight antibody target regions were identified. Most 
of which were hitherto unknown. Alignments and sequence comparisons revealed 13 of which could be 
classified as bona fide ZIKV-specific. These identified antibody target regions constitute a founding set 
of analytical tools for serological discrimination of ZIKV from other flaviviruses.
Zika virus (ZIKV), a mosquito-borne flavivirus, was first isolated from sentinel Rhesus macaques in the Zika 
forest of Uganda in 19471. The first human case was recorded in Nigeria in 1954. Before 2007, many small-scale 
epidemics were recorded in Africa and Asia2. Yap island (Micronesia) was the first area outside Africa and Asia to 
confirm human ZIKV infection3. Around one-tenth of the population of French Polynesia encountered the infec-
tion during the 2013 outbreak4. In 2015, the Brazilian ministry of health estimated around 440,000 to 1,300,000 
individuals in Brazil that may have contracted the infection. The potential of ZIKV spreading to other countries 
is high with almost one-fourth of the human population worldwide being at risk of encountering ZIKV infection. 
In regions like Europe, ZIKV transmission risk is present through high mobility and global connectivity5.
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Clinical signs of ZIKV infection are ranging from asymptomatic to mild headaches, fever, skin rashes and joint 
pain, which usually last a few days. The symptoms are unspecific and are frequently misdiagnosed as caused by 
dengue or chikungunya virus6. ZIKV is transmitted mainly by Aedes mosquitoes. Many reports discuss two addi-
tional ZIKV infection pathways: sexual intercourse and from a pregnant woman to her fetus7,8. ZIKV RNA was 
detected in the amniotic fluid of a pregnant woman9 and in the brain of an aborted fetus afflicted with microceph-
aly10. Moreover, ZIKV was linked to increased numbers of Guillian-Barré Syndrome cases in affected countries11.
ZIKV RNA can be detected in blood and saliva during the first five days of onset of symptoms, up to 21 days 
in urine and for up to one year in semen12–15. Longer persistence of anti-ZIKV antibodies in serum (IgM: up to 
two months; IgG: two years)16,17 extends the practicable diagnostic time window. On the other hand, high degrees 
of sequence identity of homologous proteins and concomitant immunological cross-reactivity among all flavi-
viruses, in particular within the various subgroups, have been reported18,19. These facts profoundly complicate 
serological diagnosis, especially in areas, where ZIKV and dengue virus are co-circulating and/or yellow fever 
vaccine is applied routinely20,21. Still, serological differentiation of ZIKV from other flaviviruses remains desirable 
and some progress towards resolving the difficulties has been announced22–24. This present study introduces a 
new approach resting on the identification, in larger numbers, of ZIKV-specific antibody targets. Specifically, 
we report comparative deconvolution of complex B cell responses against ZIKV and other flavivirus by screen-
ing corresponding sera with a microarray chip made up of overlapping peptides covering the entire amino acid 
sequence of the ZIKV genomic polyprotein. As a result, 13 short linear stretches of polypeptide sequence, scat-
tered throughout the viral proteome, were identified that exhibit exclusive reactivity towards ZIKV antisera.
Results
A (series of) positive array spot(s) indicates an antibody target and positions it within a protein sequence. In the 
context of the overlapping peptides method, the term ‘antibody target’ denotes a stretch of polypeptide chain of an 
antigen encompassing either a single linear B cell epitope or a locally clustered set thereof. In the latter case, it is 
called an antibody target region (ATR)25. Since a spots series as such often does not allow distinguishing between 
single epitope and ATR, the latter term is occasionally also used as a synonym of the generic name “antibody 
target” with epitopes regarded as extreme cases within that class.
Compiling a comprehensive list of antibody targets (epitopes, ATRs) participating in B cell responses to ZIKV 
infection and singling out from it the ZIKV-specific subset will, so the working hypothesis, enable diagnosis of 
ZIKV infection against a background of extensively cross-reacting other flaviviruses (e.g. dengue, yellow fever, 
tick-borne encephalitis, and West Nile virus). As shown earlier25, the necessary deconvolution of complex B cell 
responses to the level of contributions made by individual short stretches of polypeptide chain can be achieved 
experimentally by peptide microarray techniques. Comparing ATRs resulting from inspection of ZIKV and 
non-ZIKV flaviviral antisera will reduce the former to the ZIKV-specific subset. From this, discriminating immu-
nochemical reagents can be derived.
Immunochemical experiments. Three pools of sera from ZIKV-infected individuals and one mixed pool 
of anti-flavivirus sera were prepared and screened for serological footprints (separate experiments for IgM and 
IgG) employing peptide microarray chips (Fig. 1). Two sets of original data are displayed in Fig. 2. Positively 
responding array spots (Fig. 1) delineate antibody targets (white and blue frames in Fig. 2).
ATRs identified: Overview and crude classification. The experiments uncovered 68 ATRs, most of 
which were hitherto unknown. Of these, 21 were recognized by both IgM and IgG, 30 by IgM alone and 17 by 
IgG alone (Figs 2–4 and Supplementary Table S1). The targets are scattered across the entire proteome with no 
striking preference of envelope over non-envelope proteins (Fig. 3). From antibodies directed against the latter, 
no contribution to virus neutralization would be expected, but in the context of diagnosis they are equally useful. 
Twenty-two ATRs reacted exclusively with ZIKV sera (Figs 4 and 5, classes I and II), 13 exclusively with FlaviMix 
(classes IV and V) and 33 with both FlaviMix and at least one ZIKV pool (class III). Sequences of correspond-
ing stretches of polypeptide chain are compiled in Supplementary Tables S2 and S3. Alignments and sequence 
comparisons prompted sub-division of the ZIKV-exclusive and the FlaviMix-exclusive sets as explicated in detail 
below. Note that with “exclusive” we merely describe an observation in the present assay – in contrast to “specific” 
as an intrinsic property of a given antibody target.
Strings of amino acid residues displaying exclusive immunochemical reactivity towards ZIKV sera would 
be expected to differ substantially between ZIKV and the respective homologous sites of viruses making up the 
FlaviMix pool. This was true for 13 of 22 cases (class I, Supplementary Table S2, Fig. 5). Class I cases (such as 
ATR #2062, listed in Table 1) are characterized by a low to intermediate level of sequence identity between ZIKV 
and other flaviviruses across the respective antigen (NS4 in the case of ATR #2062) and a similarly low or lower 
degree of identity within the actual target region under consideration. The 13 class I ATRs are distributed among 
all ZIKV antigens – with the exception of antigens C and NS3 (Fig. 3). For the remaining nine cases (class II), 
sequence identity across the entire length of the respective antigen is low to intermediate but within the target 
region it is high between either ZIKV and all viruses of the FlaviMix pool (class IIa, five cases, represented in 
Table 1 by ATR #388) or ZIKV and the various Dengue subtypes only (class IIb, four cases, represented in Table 1 
by ATR #2029).
There are thirteen ATRs reacting exclusively with the FlaviMix pool. Five of these (class IV: #718, #1024, 
#1618, #2836, #3325, Supplementary Table S3) show strong similarity or identity with the respective homologous 
sites in ZIKV. Eight cases of FlaviMix-exclusive responses remain unexplained (class V: ATRs #25, #103, #1441, 
#1585, #1741, #1969, #2308, #2791, Supplementary Table S1). Anyhow, class V ATRs lack relevance to the present 
problem as they will not make any contribution to the development of a practical serological test.
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Discussion
This work marks the entry into a systematic and comprehensive search for antibody targets (epitopes, ATRs) of 
ZIKV in relation to those of other flaviviruses with the aim of identifying diagnostically useful antigenic sites 
eliciting ZIKV-specific antibodies. Despite the limited number of sera available for our analyses, some remarkable 
reactivity patterns emerged.
Antibody targets reacting with ZIKV sera pools exclusively. Among the 68 ATRs, 22 (summarized 
in Supplementary Table S2) reacted exclusively with one or more ZIKV sera pools, 13 recognized by IgM and 9 
by IgG with no overlap of the two sets. This lack of overlap is surprising in view of the fact that the combined 
processes of affinity maturation and class-switching do not qualitatively change the antigen recognition proper-
ties of an antibody: In a notional, infinitely large collection of ZIKV-positive sera, all antibody targets should be 
represented in both the IgM and the IgG set.
High local sequence conservation of an antigenic site across various virus species immediately suggests 
cross-reactivity. As cross-reactivity was missing in some cases, an explanation could, in principle, be offered 
by different antigenicity of the same stretch of polypeptide chain in homologous antigens due to different local 
three-dimensional structure (high for ZIKV, low for other flaviviruses). Some differences of 3D-structure have 
indeed been observed among different flaviviruses26.
Taken together, the findings corroborate the validity of the rationale underlying this study and the thirteen 
class I ATRs are the first bona fide candidates for being truly ZIKV-specific as required for serologically diagnos-
ing ZIKV infection against a dense background of cross-reactivity with other flaviviruses.
Cross-reacting antibody targets. Expectations that close serological scrutiny would reveal extensive 
cross-reactivity between ZIKV and other flaviviruses were borne out: At least 33 of the 68 ATRs identified in 
ZIKV and FlaviMix cross-react. As argued below, the real number is probably as high as 47 (Fig. 5). All ZIKV 
antigens carry a multitude of ATRs eliciting cross-reacting antibodies (Fig. 3) – a serious handicap for any sero-
logical ZIKV assay resting on whole antigens. Nevertheless, at least one attempt based on whole NS1 antigens 
of ZIKV and DENV (three cross-reacting ATRs by our count) has been made employing a combination of tests 
and quantitative signal comparison23. Prekumar et al. alleviate the cross-reactivity problem by focussing on 
two isolated domains of the ZIKV envelope protein that combine pronounced antigenicity with low sequence 
Figure 1. The ZIKV peptide microarray chip. (Panel A) Layout: Each chip hosts three identical arrays, each of 
which encompasses 1643 pentadekapeptides: 1136 covering the complete ZIKV Africa (AAV34151) polyprotein 
with an overlap of consecutive individual peptides of 12 amino acid residues plus 507 pentadekapeptides 
accommodating divergent sequences present in other ZIKV isolates (Brazil, USA, Senegal, French Polynesia). 
In addition, there are 96 biotin spots (green), which serve as internal positive controls and as markers of array 
boundaries (ref.23). (Panel B) Identification of positive signals: The criterion for a positive response is bright red 
fluorescence spread evenly across the entire spot area (examples marked by a blue circle).
41
SCIENTIFIC REPORTS |          (2019) 9:3648  | https://doi.org/10.1038/s41598-019-40224-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
similarity between ZIKV and DENV22. Lastly, a competition ELISA based on a ZIKV-specific monoclonal 
anti-NS1 antibody has shown remarkable selectivity and specificity21. The assay, however, is bound to miss detect-
ing ZIKV-infections of individuals that happened not to produce antibodies against that one particular epitope.
Experimental results compared with epitope prediction. Two studies have been published that aim 
at predicting B cell epitopes of ZIKV envelope proteins on the basis of theoretical considerations and homology 
to other flaviviruses27,28. Our experiments confirm 18 of these predictions and uncovered 37 additional targets 
(classes I to III, Fig. 5), not only in non-envelope proteins. On the other hand, 28 predictions could not be verified 
Figure 2. Original screening data (examples). Array spots showing positive reaction are boxed in. White boxes: 
Responses seen with FlaviMix pool (either exclusive or in combination with one or several ZIKV serum pools). 
Blue boxes: Responses seen only with ZIKV serum pools (“ZIKV-exclusives”). ATR numbers are stated next to 
corresponding boxes (Fig. 3). For experimental details refer to Materials and Methods.
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experimentally. This, however, does not necessarily indicate failed predictions but could alternatively be due, as in 
cases mentioned above, to a still incomplete collection of experimental targets. For a comprehensive comparison 
of prediction and experiment refer to Supplementary Table S4.
Non-saturating sampling of antibody targets. The notion of incomplete experimental representation 
of ZIKV ATRs in a limited number of human sera turned up in several different contexts. These are as follows. 
(i) Nine ATRs (class II) responded only to ZIKV sera despite their occurrence in homologous FlaviMix antigens 
with identical or very similar sequences. (ii) Reciprocally: Five ATRs of high sequence similarity between ZIKV
and other flaviviruses (class IV) reacted exclusively with the FlaviMix pool. (iii) Among the 22 ZIKV-exclusive
responses there is no overlap between ATRs recognized by the IgM and the IgG set of antibodies. (iv) Only a sub-
set of epitopes, previously predicted on theoretical grounds27,28, could be verified (so far) experimentally.
For every individual one of these four independent observations, incomplete ATR sampling offers an only 
tentative explanation; the notion, however, gains cogency by giving all of them a common, unified underpinning. 
As a corollary, two predictions follow: (a) Very likely, class II and class IV ATRs are true cross-reactors (Fig. 5). In 
contrast, there is no reason a priori to doubt the ZIKV specificity of the 13 members of class I. (b) A fair number 
of ZIKV ATRs are still to be discovered. This may turn out to be of practical importance in the eventual compila-
tion of a larger set of ZIKV-specific ATRs.
Conclusion and Outlook
Specific serological identification of ZIKV against a background of cross-reacting other flaviviruses requires use 
of ZIKV-specific antibody targets. Since, in principle, any single target is represented in an individual B cell 
response with a probability of less than one, high sensitivity standards can only be met by the combined applica-
tion of several targets in parallel – each characterized by highest possible antigenicity. In that sense, substantial 
headway towards the development of a ZIKV-specific diagnostic assay has been made with the discovery of 13 
bona fide ZIKV-specific ATRs as reported here.
The remaining agenda en route to a practical diagnostic procedure such as ELISA, line assay, or bead 
flow-through assay is as follows. (i) Still other potentially cross-reacting flaviviruses (e.g. Japanese encephalitis 
and spondweni viruses) need to be included. (ii) The assignment of the 13 ATRs in class I as ZIKV-specific needs 
to be further consolidated. (iii) Additional specific ATRs should be found and ranked with respect to their anti-
genicity (i.e. signal frequency in a set of test sera).
All of the above points can be addressed in a straightforward manner, larger numbers of sera being the only 
prerequisite lying outside the scope of the present study. The approach builds upon antigen amino acid sequence as 
the only indispensable knowledge and it is not limited to addressing the cross-reactivity problem of flaviviruses only.
Beyond diagnosis, peptide microarray-based, high resolution serology may contribute to gaining a better 
understanding of a number of infection-connected problems. Antibody-mediated virus enhancement, for exam-
ple, is a well-documented phenomenon associated with flaviviruses and epidemiological studies linked Zika 
Figure 3. Mapping ATRs to ZIKV polyprotein. The horizontal bar represents the 3419 residue long 
unprocessed translation product of the ZIKV genome (Genbank accession number AAV34151). Marks along 
the grey line are spaced in intervals of 500 amino acid residues. ATRs are named by the number of their residue 
lying most closely to the N-terminus (Supplementary Table S1). ATRs marked black (class I ATRs, Fig. 5 and 
Supplementary Table S2) exclusively reacted with one or more ZIKV pools. ATRs marked grey reacted with 
FlaviMix pool and with zero to three ZIKV pools.
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outbreaks to increased incidence of Guillain-Barré syndrome, a neurological autoimmune condition known to 
interact with humoral immunity29.
Materials and Methods
Serum samples and ethics statement. Samples of 42 well-characterized sera were provided by reference 
laboratories from Germany (Bernhard Nocht Institute, Hamburg), Senegal (Institut Pasteur de Dakar) and Brazil 
(University of São Paulo). The FlaviMix sera pool consists of 7 sera directed against dengue 1–4, yellow fever, tick-
borne encephalitis and West Nile viruses. The EU pool comprises 9 anti-ZIKV sera from EU travellers returning 
from Brazil. The Africa pool encompasses 19 anti-ZIKV sera from patients living in Senegal and Cape Verde. The 
Figure 4. Workflow of the study.
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Brazilian pool contains 7 anti-ZIKV sera from patients diagnosed at the University of São Paulo. All sera were 
either reference sera from the WHO collaboration center (Institut Pasteur de Dakar) or collected from patients 
during routine medical examinations or surveillance. All samples were collected between 5 to 28 days post onset 
of fever from patients tested positive with real-time PCR to the respective virus during the acute phase (>5 days). 
Samples which reacted positive to more than one virus were excluded from the study. Patients had given consent 
according to national and international ethical regulations. All samples were handled anonymously.
ZIKV peptide microarray scanning chips. The ZIKV proteome of the African strain is made up of seven 
antigens (prM not counted as a separate module) with a cumulative length of 3419 amino acid residues30. Antigen 
sequences were broken up into 1136 pentdecapeptides with a consecutive overlap of 12 residues representing the 
ZIKV African strain (GenBank accession number AAV34151). These were synthesized via SPOT synthesis31, passed 
through the SC2 process32 and spotted onto glass microscope slides (AIMS Scientific Products GmbH, Berlin, 
Germany) as illustrated in Fig. 1A (upper part of each of three identical arrays displayed in Fig. 1A). Each of the 
(smaller) lower array parts accommodates 507 additional pentadecapeptides that cover sequence stretches differ-
ing from the reference sequence in other ZIKV strains (Brazil, ALU33341; USA, AOS90225; Senegal, AHL43504; 
French Polynesia, AHZ13508). In addition, 96 spots of a biotin/(β-alanine)2/cellulose conjugate were deposited on 
the chips as positive controls and for marking array boundaries. After staining, they light up green (Fig. 1A).
Chip screening procedure. In each individual experiment, a ZIKV microarray chip was washed with abso-
lute ethanol for 3 min, then three times for 3 min each with TBS (50 mM Tris base, 150 mM NaCl, HCl ad pH 
7.6). After incubation with blocking buffer (TBS, 2% casein, 0.1% Tween-20) overnight, the chip was washed 
with T-TBS (TBS, 0.1% Tween-20) for 3 min. Thereafter, 70 µl of any of the four serum pools, diluted 120-fold, 
were added onto the chip. The chip was incubated in a humidified chamber at 4 °C overnight. Thereafter, the chip 
was washed three times for 5 min each with T-TBS. To visualize the binding of primary antibodies, the following 
was added onto the chip: 60 µl of blocking buffer containing Cy3-conjugated mouse anti-biotin and Alexa Fluor 
647-conjugated goat antibody directed against either human IgG or human IgM (240-fold dilution of stock solu-
tions prepared according to instructions of the commercial supplier, Jackson Immunoresearch Laboratories, West 
Grove, PA, USA). The chip was kept in a humidified chamber at room temperature for 1.5 hours. Subsequently, 
the chip was washed twice for 5 min with T-TBS, three times with distilled water for 5 min each, and dried by
dipping into acetonitrile for 10 sec before visualization with an Agilent DNA microarray scanner. Each serum
pool was tested in triplicate (three individual chips, corresponding to nine arrays total). For unknown reasons,
all four sera pools produced atypically high levels of background which precluded application of the previously 
developed, automated spot calling procedure25. Therefore, array patterns were visually inspected and positive
responses were identified in two steps – with the burden of safeguarding against false positives laid predominantly
on stringent selection in step 1: (i) Individual signals were called positive if they showed bright red fluorescence
spread uniformly across the entire spot area (Fig. 1B). (ii) A spot was taken as indicating an antibody target, if it
passed step 1 in at least two arrays of the same chip with at least two out of three separate chips.
Sequence alignment. Bioinformatics: Experimentally determined ATRs were aligned to viral polyproteins 
using the pairwise alignment tool of the GENEIOUS program package (Biomatters Ltd, Auckland, New Zealand). 
Query sequences were composed of the respective ATR plus fifty amino acid residues each on both sides – all 
taken from the reference ZIKV strain (GenBank accession number: AAV34151).
Figure 5. Classification of 68 experimentally identified ATRs. Roman numerals: Name of class. Arabic 
numerals: Number of ATRs in respective class. Class I: ZIKV-exclusives with low similarity to homologous 
sequences of FlaviMix viruses (residue identity <80%). Class II: Same with high similarity (residue identity 
≥80%). IIa: Similarity present in sequences of all viruses making up FlaviMix pool. IIb: Same but similarity 
only observed for Dengue subtypes. Class III: ATRs eliciting antibodies responding to both ZIKV and FlaviMix 
sera pools. Class IV: FlaviMix-exclusives with high similarity between ZIKV and FlaviMix. Class V: FlaviMix-
exclusives with no clear-cut location on polyprotein map of any virus represented in FlaviMix. Numbers of cases 
are graphically represented as bar areas. For usage of the term “exclusive” refer to main text.
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Ethical statement. No ethical approval was required as all sera were either reference sera from the WHO 
collaboration center (Institut Pasteur de Dakar) or collected from patients during routine medical examinations 
or surveillance. All samples were handled anonymously.
Data Availability
All data produced during this study were included in the manuscript. Original data files are available upon re-
quest to the corresponding author.
ATR and Class Virus (accession number)






Id (%) Antig. 
within Subgroup
ATR #2062 (NS4) 
[Class I: 13 members] 
IgM (e,a,B) IgG (e,a,b)
Zika (AAV34151, Africa) 100 DGTTNNTIMEDSVP-AEVWTKY 100 100
Zika (AOS90225, USA) 96.4 ..............-.....RH 100 96.5
Zika (ALU33341, Brazil) 96.4 ..............-.....RH 90.9 97.1
Zika (AHZ13508, Fr. Polynesia) 96.5 ..............-.....RH 90.9 96.6
Zika (AHL43504, Senegal) 99.0 ..............-....... 90.9 99.1
Dengue 1 (NP_059433) 55.5 (98.6) ..ER..QVL.ENMD-V.I...E 40.9 45.8 98.9
Dengue 2 (NP_056776) 55.5 (97.7) ..VK..Q.L.EN.E-V.I...E 50.0 49.3 98.1
Dengue 3 (YP_001621843) 56.2 (98.7) ..QR..Q.L.ENMD-V.I...E 45.5 47.0 98.1
Dengue 4 (NP_073286) 56.3 (98.3) T.ER..Q.L.ENME-V.I..RE 36.4 47.3 98.8
Yellow Fever (NP_041726) 46.6 (96.4) E.PEEHE.LN..GETVKCRAPG 22.7 34.4 96.3
West-Nile (YP_001527877) 57.3 (98.6) ..PRT...L..NNE-V..I..L 50.0 43.0 98.2
TBE (NP_043135) 41.5 (95.8) E.PEA.AVD.A.GDLVTFRSPN 22.7 29.5 96.1
ATR #388 (E) [Class 
IIa: 5 members] IgM 
(e,a,b) IgG (E,a,b)
Zika (AAV34151, Africa) 100 DRGWGNGCGLFGKGS 100 100
Zika (AOS90225, USA) 96.4 ............... 100 96.4
Zika (ALU33341, Brazil) 96.4 ............... 100 96.2
Zika (AHZ13508, Fr. Polynesia) 96.5 ............... 100 94.4
Zika (AHL43504, Senegal) 99.0 ............... 100 98.9
Dengue 1 (NP_059433) 55.5 (98.6) ............... 100 58.9 98.5
Dengue 2 (NP_056776) 55.5 (97.7) ..............G 93.3 54.5 98.0
Dengue 3 (YP_001621843) 56.2 (98.7) ............... 100 58.7 98.5
Dengue 4 (NP_073286) 56.3 (98.3) ..............G 93.3 56.7 98.3
Yellow Fever (NP_041726) 46.6 (96.4) ............... 100 43.3 96.9
West-Nile (YP_001527877) 57.3 (98.6) ............... 100 54.0 98.9
TBE (NP_043135) 41.5 (95.8) ......H........ 93.3 39.1 98.8
ATR #2029 (NS4) 
[Class IIb: 4 members] 
IgM (e,A,B) IgG (e,a,b)
Zika (AAV34151, Africa) 100 TFVELMKRGDLPVWL 100 100
Zika (AOS90225, USA) 96.4 ............... 100 96.5
Zika (ALU33341, Brazil) 96.4 ............... 100 97.1
Zika (AHZ13508, Fr. Polynesia) 96.5 ............... 100 96.6
Zika (AHL43504, Senegal) 99.0 ............... 100 99.1
Dengue 1 (NP_059433) 55.5 (98.6) ......R........ 93.3 45.8 98.9
Dengue 2 (NP_056776) 55.5 (97.7) ...D..R........ 86.7 49.3 98.1
Dengue 3 (YP_001621843) 56.2 (98.7) ......R........ 93.3 47.0 98.1
Dengue 4 (NP_073286) 56.3 (98.3) ......R........ 93.3 47.3 98.8
Yellow Fever (NP_041726) 46.6 (96.4) V.R..VRNC...... 60.0 34.4 96.3
West-Nile (YP_001527877) 57.3 (98.6) N.L..LRTA...... 60.0 43.0 98.2
TBE (NP_043135) 41.5 (95.8) H.RH.LTHC.FTP.. 33.3 29.5 96.1
Table 1. Properties of ZIKV-exclusive ATRs. Three ATRs exclusively responding to ZIKV sera are illustrated, 
one representative case of each class I, IIa and IIb (for classification refer to Fig. 5; a comprehensive compilation 
of all ZIKV-exclusive ATRs and their sequence characteristics is given in Supplementary Table S2). Id values, 
if not stated otherwise, denote % sequence identity with reference strain Zika (AAV34151, Africa) of genomic 
polyprotein, respective antigen and ATR as indicated in column headers. In addition, Id values indicating 
bandwidths of sequence variation within subgroups of non-ZIKV flaviviruses (polyprotein or individual 
antigen) are listed. These were derived as follows. (i) A consensus sequence was computed for each subgroup. 
(ii) For each member of the respective subgroup percent residue identity with the consensus sequence was 
calculated. (iii) The mean value of these was defined as “Id within subgroup”. Alignments were performed as 
described in Materials and Methods. Symbols for provenances of ZIKV-sera are as follows. E: EU pool, A: 
African pool, B: Brazilian pool. Capital letters (E, A, B) indicate positive signal observed with respective sera 
pool, while small letters (e, a, b) represent lack of reactivity with either IgM or IgG.
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Chapter VI: General Discussion 
In general, the work of this PhD thesis consists of three parts. In the first part (Chapter 
II), a field applicable method was developed in order to extract nucleic acids from 
complex samples. The second part (Chapter III and IV) of the PhD study focused on 
the genomic identification of pathogens by applying diagnostic metagenomics in the 
field. The third part of this thesis was dedicated to the identification of specific 
serological markers, especially those useful for the species differentiation among the 
genus of flaviviruses. 
 
Why Mycobacterium avium subspecies paratuberculosis, Zika virus and Foot 
and Mouth disease virus were selected as model pathogens in this PhD work 
MAP, causing paratuberculosis or John´s disease, is a Gam-positive, non-motile, non-
spore forming and acid-fast bacterium. It infects mainly ruminants leading to diarrhoea 
and losses in weight and milk production [103, 104]. The number of infected and 
shedding animals within a herd is hard to estimate, as the bacteria is expelled from the 
body in intervals and clinical signs of the paratuberculosis appeared only in a small 
number of infected animals [63, 105]. Faecal-oral route is seen as the main way of 
transmission [106]. Therefore, the identification of the bacterium in faeces is very 
important. However, culturing of the bacteria, which is seen as the gold standard of 
diagnostics, needs at least 12 weeks to result [107]. As stated in Chapter II, nucleic 
acid amplification assays are available for the detection of MAP, but the sensitivity of 
these methods depends highly on the performance of the nucleic acid extraction. The 
extraction of DNA from MAP in faecal samples is very challenging. The bacteria are 
resistant to many chemical and physical forces due to the thick, lipid and 
polysaccharose rich cell wall. In addition, the diverse compounds in the faeces may 
inhibit the reaction [108-110]. Thus, MAP is an optimal candidate for the development 
of a protocol for nucleic acid extraction, which is also suitable for other challenging 
pathogens and sample matrixes.  
FMDV is a highly contagious virus from the family of Picornaviridae. The virus causes 
high economical losses by infecting mainly cloven-hoofed animals. The European 
Union is free from the virus, but there is a risk of re-emergence, as the virus is endemic 
in Northern Africa and the Middle East [111]. A critical point in transmission is the viral 
genome, which can directly act as messenger RNA within the host without the need of 
an intact virion [112]. The seven serotypes of FMDV have no cross-reactivity between 
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each other. Accordingly, vaccination provides no cross-protection. In addition, there is 
a strong genetic variability within each serotype [113]. ELISA is the common laboratory 
method for serotype identification [114] but there is a lack of approaches for 
differentiation on genomic base and at PON. All molecular assays like RPA [115] and 
real-time PCR [116] detect only the virus genome but cannot be used for FMDV 
differentiation. Attempts to apply such assays for detection of the FMDV serotypes 
were only restricted to the strains circulating in a particular area [117, 118]. Therefore, 
FMDV is a good example for applying sequencing as a universal method for the 
discrimination between closely related viral strains.  
ZIKV (Figure 6) is a prominent representative of the genus of flaviviruses [119]. More 
than 50 arthropod borne species are located in this genus (Figure 7, [120]) infecting 
not only human but also wild and domestic animals. Flaviviruses are listed in both the 
OIE list of highly infectious diseases for animals as well as the neglected viral diseases 
by the WHO [100, 121, 122]. Besides ZIKV, the genus of flaviviruses includes 
pathogens like Dengue, Yellow Fever virus, West Nile and Japanese Encephalitis virus 
[123].  
ZIKV was declared temporarily as a public health emergency by the World Health 
Organization in 2016 due to the South American outbreak at that time [124]. Although 
ZIKV is no longer seen as a public health emergency, the virus is still listed as priority 
disease [125] .  
Figure 6: Schematic picture of ZIKV (Panel A) Source: ViralZone [126]. 
The reservoir of ZIKV is not clearly identified, although non-human primates are shown 





other domestic animals, but was only seen on antibody basis [128], which is not a clear 
proof due to the antigenic homology to other flaviviruses. According to the United 
States Centers for Disease Control and Prevention (CDC), there are no reports of ZIKV 
infected animal despite a single study, which showed that identified ZIKV positive 
animals have no clinical signs or the potential to spread the virus [129]. 
ZIKV and other flaviviruses like the Dengue and West Nile virus often circulate in the 
same regions [130-132] and have similar clinical signs like unspecific fibril illness [133], 
but clinical manifestations within the genus can differ from haemorrhagic fever to 
vasculopathy or encephalitis [134]. The viremia lasts only for around five days with a 
very low virus concentration in the blood (3 viral particles per ml blood, [135, 136]). 
However, most sequencing methods require around 104 molecules per tested sample 
to generate a nucleic acid sequence [137]. Therefore, ZIKV was considered a suitable 
virus to proof the concept of combining random isothermal amplification and nanopore 
sequencing in order to achieve the required amount of DNA needed (Chapter III). 
Flaviviruses have a high antigenic homology to each other and cross-reactivity in 
immunological tests is quite common (Figure 7, [123, 138]). Hence, flaviviruses can be 
sorted into groups of two or more viruses, which are distinct from each other, however, 
related serologically. These groups are called serogroups. Within the serogroup, 
viruses more antigenically close to each other are forming a serocomplex [139, 140]). 
ZIKV is in the same serogroup of dengue virus and ZIKV and Spondweni virus are 
forming a serocomplex (Figure 7). A discrimination between acute ZIKV infection and 
a previous Dengue infection is difficult because both are located under the same 
serogroup [136]. 
Thus, identification of ZIKV specific serological markers in order to identify an ZIKV 
infection against the background of dengue virus and other ongoing or previous 





Figure 7: Phylogenetic relationship of selected flaviviruses based on the divergence of the full amino acid 
sequences. The branch labels show the difference between the single serogroups and species, coloured 
background displays which viruses form a serogroup. 
 
The extraction of bacterial DNA in the field 
The rapid isolation of nucleic acids in the field is urgent for the diagnostics on a 
genomic or metagenomic base at POC and PON. In this PhD work, a rapid and 
sensitive protocol for the extraction of bacteria was developed (Chapter II). The major 
advantage of this protocol is the bead beating step in the field, which facilitates the 
isolation of DNA from Gram-positive bacteria with a strong cell wall [141].  
The SpeedXtract method (Qiagen Hilden, Hilden, Germany) is a rapid nucleic acid 
extraction method which can easily be performed in the field requiring a heating source 
capable of 95 °C and a magnetic stand. The protocol includes only a few pipetting 
steps and can be taught to untrained persons in less than one day. 
The technology relies on the reverse purification of the sample, i. e. after cell lysis, the 
inhibitors for nucleic acid amplification like cell membranes are removed from the 
supernatant, but other molecules like DNA and RNA in addition to coloured particles 
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(bile salts, [142]) remain. Therefore, the technology is only compatible with 
amplification methods resistant to inhibitors like RPA, but not with PCR. 
Although the SpeedXtract method was used for the nucleic acid extraction from 
parasites and viruses before [68, 143-145], the protocol developed in this PhD thesis 
is the first, using the reverse purification technology for bacteria. 
 
Sequencing protocols for the rapid identification of the causative agent at 
outbreak situations 
Metagenomic diagnostics are a reliable and necessary tool for the identification of 
pathogens responsible in an outbreak situation. In this PhD work, two protocols were 
developed for the use of the nanopore sequencing in the field. The first protocol is 
dedicated to the sequencing of ZIKV (Chapter III). As the viral load of ZIKV within a 
sample is only around 3 particles per millilitre of blood [135], a random isothermal 
amplification step was implemented after reverse transcription and second strand 
synthesis in order to increase the total yield of the of DNA.  
Sequencing of RNA viruses at PON was done before employing nanopore sequencing. 
Quick et al. performed reverse transcription PCR (RT-PCR) using 38 pairs of Ebola 
virus specific primers targeting the whole genome before sequencing. This 
combination of targeted RT-PCR and nanopore sequencing was applied to reduce the 
human background within the sequences. The produced sequences covered around 
97 percent of the complete viral genome [57]. As the specific primers were selected 
from a known reference sequence, variants in the targeted genome sequence might 
have led to a decrease in priming efficacy. Moreover, large rearrangements like 
insertions or deletions are only detected, when flanked by primers [146]. These might 
be the reason for the incomplete sequencing of the full Ebola genome. In contrast, the 
random hexamer primers and Multiple Displacement Amplification technology applied 
in this PhD work hybridize to the cDNA distributed over the whole genome sequence 
and produce amplicons between 2-100 kb [147]. Therefore, the random isothermal 
amplification in combination with nanopore sequencing is superior by yielding long 
sequences and full coverage of the sequenced genome without the need of heavy and 
complex devices such as a thermocycler. 
The second sequencing protocol was developed for the rapid serotyping of FMDV in 
the field via metagenomic diagnostics (Chapter IV). The FMDV genome consists of a 
single stranded positive sense RNA (ss-RNA) with a poly-A tail at the 3`end [148]. In 
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order to create a full-length DNA, a poly-T reverse primer was applied together with 
the SMART-technology (Zhu et al., 2001, [149]). As consequence, a non-fragmented 
long DNA molecule was produced. Sequence analysis using long reads has the 
advantage of being more accurate and deliver results similar to the natural situation 
[150]. 
The major breakthrough approach of the two metagenomic diagnostics studies is the 
combination of direct sequencing with the local offline BLAST search. The 
implementation of an offline BLAST database in outbreak situations liberates from the 
need of a stable internet connection especially under field settings. The GENEIOUS 
v9.1.6 (Biomatters Ltd., Auckland, New Zealand) was employed for the offline 
database and sequence analysis. As the program is very user friendly, a bioinformatic 
education is not needed.  
Metagenomic diagnostics in the field is only possible with portable sequencing devices. 
Hitherto, the MinION device is the only portable sequencer suitable for the use in the 
field. Nevertheless, an expensive high-performance computer was required for real-
time sequence data collection and analysis. To improve the field applicability, mobile 
data acquisition hardware was developed (MinION (Figure 5), MinIT, or Mk1C by 
ONT). All these developments allowed sequencing without the drawbacks of using 
incompatible laptop. Another issue, the quality of the sequencing data depends on the 
amount and condition of the DNA [151]. Therefore, the DNA integrity must be checked 
after each step of the library preparation to assure an excellent sequencing run.  
 
Differentiation of Zika virus to other flaviviruses using peptide microarrays 
Most serological tests for the identification of flaviviruses detect antibodies directed 
against the envelope (E) protein or non-structural 1 (NS1) protein [152]. The E protein 
consists out of three parts (DI-DIII) which are organized as antiparallel homodimers. 
Antibodies can attach easily to the outer parts of the virus and be directed to more than 
one part of the enveloped (inter dimer epitope, [153]) The NS1 protein is highly 
conserved among all flaviviruses and takes part in immune evasion and genetic 
replication of the virus [154]. Virus specific epitopes to other non-structural proteins 
were also identified [155, 156], but not deeply characterized. In this PhD work, a 
peptide microarray was applied to identify 68 ATRs, from which 13 were considered 
as ZIKV specific. These ATRs are potential candidates for the development of simpler 




Several attempts were made to differentiate ZIKV to other flaviviruses on a serological 
basis. Premkumar et al. propose two specific epitopes by prediction followed by 
producing and testing the respective synthetic antigens in ELISA [157]. The study 
focused only on the envelope proteins and did not consider the other immunogenic 
proteins. In two studies, ELISA assays were developed [158, 159] but each of these 
assays only utilized a single ZIKV epitope. All three studies concentrated on the 
differentiation of ZIKV to Dengue virus and did not consider other flaviviruses. Other 
authors employed peptide microarray chips to identify epitopes for discrimination of 
ZIKV to other flaviviruses [160, 161]. The first study relies on macaque sera [160], 
while the second study targeted a sole antigenic site on NS2b [161]. The epitope 
mentioned in these studies was partly mapped in this PhD work (Chapter V; epitope 
1441). Surprisingly, the epitope was not seen as ZIKV specific but recognized only by 
FlaviMix pool sera instead. 
Mapping targets of antibodies against ZIKV is crucial, particularly to elucidate the cross 
reactivity to other flaviviruses [123, 162, 163] in order to provide accurate identification 
of infected cases. Several methods (e.g. phage display libraries and peptide-based 
ELISA) have been used [164]. These, however, suffer from cumbersome handling and 
the need for large amounts of sera. The use of peptide microarrays has the advantage 
of identifying simultaneous antibody binding sites over the whole polyprotein in high-
resolution at individual epitope level [165]. Thousands of target peptides can be 
analysed in one run by using only a small volume of diluted sample with a high 
reproducibility [166]. The technique can even identify shifts in epitopes on the same 
protein [167].  
A big drawback of the peptide microarrays is that only linear epitopes can be identified, 
conformational epitopes or discontinuous epitopes can only be partly mapped [168]. In 
order to map other epitope types, alternative methods should be applied [169]. The 
peptides printed onto the microarray glass slide are produced in relatively large volume 
which then can be stored in a deep freezer for later use. Due to this kind of storage, a 
variation in performance between the different batches of microarray slides was 
recorded [170]. In this PhD work, studies using peptide microarrays produce a huge 
amount of data. Read out and interpretation of the data can be achieved by special 
bioinformatics tools [171-173]. Nevertheless, the presence of a strong background 
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interferes with the automated positive signal recording. A manual data acquisition was 
necessary to count the true positive signals, but it was time consuming.  
The complexity of ZIKV clinical picture and possible multiple transmission routes as 
well as high antibody cross-reactivity between flaviviruses make it difficult to identify 
the ZIKA clinical cases and decode the ZIKV pathogenesis. There is a need to apply 
novel technologies in order to reveal the glaring discrepancy between the complex 
clinical picture of ZIKV and the lack of scientific evidence bearing explanatory potential. 
The ZIKV peptide microarray allowed high-resolution mapping of the ZIKV antibody 
linear target, which can be used to develop a POCT. Nevertheless, additional 
investigations are essential to determine the biological function of these antibodies.  
 
Conclusion 
In the last three decades, more than 30 new infectious diseases emerged, most of 
them zoonotic [174]. To prevent them from crossing species barriers or spread 
globally, a reliable method for the identification of pathogens is needed urgently. 
Current POCT and PONT are often designed for the detection of a single pathogen 
and do not have the diagnostic capabilities of laboratory tests. A platform suitable for 
the investigation of multiple pathogens is needed in order to identify the causative 
pathogen of an outbreak. Once the pathogen is detected, a target-specific rapid test 
kit must be deployed to recognize the diseased individuals.  
This PhD work presented several approaches for better development of diagnostics 
tests at PON and POC. On one hand, the fast and accurate extraction of DNA enabled 
the use of molecular assays at PON. On the other hand, the adaption of the two 
sequencing protocols to the mobile suitcase laboratory plus the offline data analysis 
provided metagenomic diagnostics under field conditions. The use of peptide 
microarray technology for identification of a bundle of potential ZIKV specific 
immunologic markers was demonstrated. This will lead to better specific serological 
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Supplementary Figure S1 
Figure S1. A: RPA results of DNA extracted either by the QIAamp DNA Mini Blood Kit (blue) or the 
MAP SpeedXtract protocol with use of Proteinase K (purple) and without (pink).  
B: Performance of the DNA extraction protocols #7 to #10. 
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Supplementary File S1 
MAP SpeedXtract Protocol #10 
1. Preparations:
o Switch on the heat block and adjust the temperature to 95°C.
Please be sure that the heat block reach 95°C before starting
with the extraction protocol.
o Prepare for each sample two 1.5 ml tubes containing 40µl
water, two Precellys SK 38 tubes and two appropriate tubes for
storage. Label them with the sample ID.
o Vortex SpeedXtract Suspension A for 30 seconds to re-
suspend magnetic particles.
2. SpeedXtract protocol:
o Add 100 mg of the sample to 500 µl Buffer SL in a Precellys
SK 38 tube.
o As an extraction control, please add 500 µl Buffer SL in a
Precellys SK 38 tube.
o Place tubes on a Vortex and mix for 1 min
o 60 µl of Suspension A to the sample.
o Mix well for 10 seconds by vortexing or inverting.
o Incubate tubes at 95°C for 15 minutes. Remove the tube every
two minutes from the heat block and vortex.
o Remove sample tubes from heat block after 15 minutes and
either shake down or tap on a bench to remove condensate
from the lid.
o Transfer sample tubes to a magnetic stand and incubate at
room temperature for 2 minutes.
o Carefully open sample tubes and transfer 10 µl of the
supernatant to a 1.5 ml tube containing 40 µl water to dilute the
sample 1:5.
o Put dilute sample direct in RPA and store the rest of the sample
at -20°C in an appropriate tube.
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Additional file 1: Foot and Mouth Disease Virus Direct cDNA native Barcoding 
Protocol for library preparation 
Before Start prepare the following: 
Direct cDNA Sequencing Kit (Oxford Nanopore, Oxford, UK; SQK-DCS108) 
Native Barcoding Kit 1D (Oxford Nanopore, Oxford, UK; EXP-NBD103) 
VN primer, VNP (5' - 5phos/ 
ACTTGCCTGTCGCTCTATCTTCTTTTTTTTTTTTTTTTTTTTVN - 3') (TIB MOLBIOL, 
Berlin, Germany) 
Strand Switching primer, SSP (5´-TTTCTGTTGGTGCTGATATTGCTGCCATTACGGCC 
mGmGmG with 2' O-methyl RNA bases-3´) (TIB MOLBIOL, Berlin, Germany) 
PR2 Primer 5´-TTTCTgTTggTgCTgATATTgC-3´ (TIB MOLBIOL, Berlin, Germany) 
200 μl tubes (Eppendorf AG, Hamburg, Germany; 022510509) 
1.5 ml Eppendorf DNA LoBind tubes (Eppendorf AG, Hamburg, Germany; 022431021) 
Nuclease-free water 
Freshly prepared 70% ethanol in nuclease free water 
LongAmp Taq 2X Master Mix (New England Biolabs, Ipswich, MA, USA; M0287) 
Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA; A63880) 
SuperScript IV reverse transcriptase, 5x RT buffer and 100 mM DTT (ThermoFisher 
Scientific, Waltham, MA, USA; 18090050) 
NEBNext End repair / dA-tailing Module (New England Biolabs, Ipswich, MA, USA; E7546) 
NEB Blunt/TA Ligase Master Mix (New England Biolabs, Ipswich, MA, USA; M0367)  
Set heating block to 65°C, 42°C, 37°C 
Save the programs listed below into a thermal cycler 
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A) Reverse transcription and strand-switching
1. Prepare the following reaction:
2. Mix gently by flicking the tube, and spin down.
3. Incubate at 65 °C for 5 minutes and then snap cool on a pre-chilled freezer block.
4. Add 2 µl SSP (10 pmol)
5. Mix gently by flicking the tube, and spin down.
6. Incubate at 42 °C for 3 minutes.
7. Add 4 µl SuperScript™ IV VILO™ Master Mix and 6.5 µl nuclease free water
8. Mix gently by flicking the tube, and spin down.
9. Incubate using the following protocol:
Cycle step Temperature Time No. of cycles 
Reverse transcription 50 °C 15 mins 1 
Strand switching 42 °C 10 mins 1 
Heat inactivation 80 °C 30 mins 1 
Hold 4 °C 
B) RNA degradation and second strand synthesis
1. Transfer the sample to a 1.5 ml DNA LoBind Eppendorf tube.
2. Add 17 μl of resuspended AMPure XP beads to the reaction and mix by flicking the
tube.
3. Incubate on a Hula mixer (rotator mixer) for 5 minutes at RT.
4. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample
5. Pellet on a magnet.
6. Keep the tube on the magnet, and pipette off the supernatant.
Reagent Volume 
250-500 ng RNA x μl
VNP (10 pmol) 2.5 μl 
-10 mM dNTPs 1 μl 
RNase-free water x μl 
Total volume 7.5 μl 
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7. Keep on magnet, wash beads with 200 μl of freshly prepared 70% ethanol without
disturbing the pellet.
8. Remove the 70% ethanol using a pipette and discard.
9. Repeat.
10. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample.
11. Pipette off any residual 70% ethanol.
12. Briefly allow to dry for 10 min.
13. Remove the tube from the magnetic rack and resuspend pellet in 20 μl Nuclease-
free water.
14. Incubate on a Hula mixer (rotator mixer) for 10 minutes at RT.
15. Pellet beads on magnet until the eluate is clear and colourless.
16. Remove and retain 20 μl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube.
17. Prepare the following reaction in a 0.2 ml thin-walled PCR tube:
Reagent Volume 
2x LongAmp Taq Master Mix 25 μl 
PR2 Primer (PR2, 10 pmol) 2 μl 
Reverse-transcribed sample from above 20 μl 
Nuclease-free water 3 μl 
Total 50 µl 
18. Incubate using the following protocol:
Temperature Time No. of cycles 
94 °C 1 min 1 
50 °C 1 min 1 
65 °C 15 min 1 
4 °C ∞ 1 
19. Transfer the sample into a clean 1.5 ml Eppendorf DNA LoBind tube.
20. Add 40 μl of resuspended AMPure XP beads to the reaction and mix by flicking the
tube.
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21. Incubate on a Hula mixer (rotator mixer) for 5 minutes at RT.
22. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample
23. Pellet on a magnet.
24. Keep the tube on the magnet, and pipette off the supernatant.
25. Keep on magnet, wash beads with 200 μl of freshly prepared 70% ethanol without
disturbing the pellet.
26. Remove the 70% ethanol using a pipette and discard.
27. Repeat.
28. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample.
29. Pipette off any residual 70% ethanol.
30. Briefly allow to dry for 10 min.
31. Remove the tube from the magnetic rack and resuspend pellet in 21 μl Nuclease-
free water.
32. Incubate on a Hula mixer (rotator mixer) for 10 minutes at RT
33. Pellet beads on magnet until the eluate is clear and colourless.
34. Remove and retain 21 μl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube.
35. Analyse 1 μl of the strand-switched DNA for size, quantity and quality.
C) End-prep (NEBNext End repair / dA-tailing Module (New England Biolabs, Ipswich,
MA, USA; E7546)
1. Perform end repair and dA-tailing of fragmented DNA as follows:
Reagent Volume 
cDNA sample 20 μl 
Nuclease-free water 30 μl 
Ultra II End-prep reaction buffer 7 μl 
Ultra II End-prep enzyme mix 3 μl 
Total 60 µl 
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2. Incubate using the following protocol:
Temperature Time No. of cycles 
20 °C 5 min 1 
65 °C 5 min 1 
3. Transfer the sample into a clean 1.5 ml Eppendorf DNA LoBind tube.
4. Add 60 μl of resuspended AMPure XP beads to the reaction and mix by flicking the
tube.
5. Incubate on a Hula mixer (rotator mixer) for 5 minutes at RT.
6. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample
7. Pellet on a magnet.
8. Keep the tube on the magnet, and pipette off the supernatant.
9. Keep on magnet, wash beads with 200 μl of freshly prepared 70% ethanol without
disturbing the pellet.
10. Remove the 70% ethanol using a pipette and discard.
11. Repeat.
12. Remove residue from lid by tapping the tube on the bench or spinning down slightly
the sample.
13. Pipette off any residual 70% ethanol.
14. Briefly allow to dry for 10 min.
15. Remove the tube from the magnetic rack and resuspend pellet in 30 μl Nuclease-
free water. Incubate for 2 min.
16. Pellet beads on magnet until the eluate is clear and colourless.
17. Remove and retain 30 μl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube.
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D) Barcoding and Adapter Ligation 
 










2. Mix gently by flicking the tube and spin down 
 
3. Incubate reaction for 10 min at room temperature. 
 
4. Add 50 μl of resuspended AMPure XP beads to the reaction and mix by flicking the 
tube. 
 
5. Incubate on a Hula mixer (rotator mixer) for 5 minutes at RT. 
 
6. Remove residue from lid by tapping the tube on the bench or spinning down slightly 
the sample 
 
7. Pellet on a magnet. 
 
8. Keep the tube on the magnet, and pipette off the supernatant. 
 
9. Keep on magnet, wash beads with 200 μl of freshly prepared 70% ethanol without 
disturbing the pellet. 
 




12. Remove residue from lid by tapping the tube on the bench or spinning down slightly 
the sample. 
 
13. Pipette off any residual 70% ethanol. 
 
14. Briefly allow to dry for 10 min. 
 
15. Remove the tube from the magnetic rack and resuspend pellet in 30 μl Nuclease-
free water. Incubate for 2 min. 
 
16. Pellet beads on magnet until the eluate is clear and colourless. 
 
17. Remove and retain 26 μl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube. 
 
18. Quantify 1 μl of eluted sample. 
 
Reagent Volume 
end-prepped cDNA sample 22,5 μl 
Native Barcoding Kit 1D 2.5 μl 
Total 25 µl 
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19. Pool the barcoded samples at the desired ratio in a DNA LoBind 1.5ml Eppendorf 
tube. Aim for as high a concentration as possible which does not exceed 700 ng 
total. If the total volume is > 30 μl, perform a 2.5x AMPure clean up and elute in 30 
μl of nuclease free water. 
 
20. Dilute 700 ng pooled sample to 50 μl in Nuclease-free water. 
 
21. Thaw and prepare the sequencing kit and NEB Blunt/TA Ligase Master Mix 
reagents as follows: 
 
Reagent Temperature 
ABB Buffer (ABB) RT 
Elution Buffer (ELB) RT 
Barcode Adapter Mix (BAM) on ice 
Running Buffer with Fuel Mix (RBF) on ice 
NEB Blunt/TA Ligase Master Mix on ice 
 
22. Take the pooled and barcoded DNA and perform adapter ligation as follows, mixing 
by flicking the tube between each sequential addition. 
 
Reagent Volume 
700 ng pooled barcoded sample 50 μl  
Barcode Adapter Mix (BAM) 20 μl  
NEB Blunt/TA Ligase Master Mix 25 μl 
Total 95 µl 
 
23. Mix gently by flicking the tube, and spin down. 
 
24. Incubate the reaction for 10 minutes at RT. 
 
25. Add 40 μl of resuspended AMPure XP beads to the adapter ligation reaction from 
the previous step and mix by pipetting. 
 
26. Incubate on a Hula mixer (rotator mixer) for 5 minutes at RT. 
 
27. Place on magnetic rack, allow beads to pellet and pipette off supernatant. 
 
28. Add 140 μl of the ABB buffer to the beads. Close the tube lid, and resuspend the 
beads by flicking the tube.  
 





31. Remove the tube from the magnetic rack and resuspend pellet in 12 μl Elution 
Buffer (ELB). 
 
32. Pellet beads on magnet until the eluate is clear and colourless. 
75
33. Remove and retain 12 μl of eluate into a clean 1.5 ml Eppendorf DNA LoBind tube.
34. Dispose the pelleted beads
35. The prepared library is used for loading into the MinION Flow Cell. Store the library
on ice until ready to load.
E) Priming the Flowcell R9.4
1. Before sequencing checklist.
2. Prepared library on ice.
3. Set up computer to run MinKNOW Hardware check complete.
4. Connect sequencing device to computer with SpotON Flow Cell inserted.
5. Set up Desktop Agent (if applicable) and complete Flow cell check.
6. Prepare the flow cell priming mix in a clean 1.5 ml Eppendorf DNA LoBind tube:
Reagent Volume 
RBF 576 μl 
Nuclease-free water 624 μl 
Total 1200 µl 
7. Load 800 μl of the priming mix into the flow cell via the priming port, avoiding the
introduction of air bubbles. Wait for 5 minutes.
8. Prepare the library for loading as follows:
Reagent Volume 
RBF 35.0 μl 
LLB 25.5 μl 
Nuclease-free water 2.5 μl 
DNA library 12 μl 
Total 75 μl 
9. Complete the flow cell priming:
10. Gently lift the SpotON sample port cover to make the SpotON sample port
accessible.
11. Load 200 μl of the priming mix into the flow cell via the priming port (not the SpotON
sample port), avoiding the introduction of air bubbles.
12. Mix the prepared library gently by pipetting up and down just prior to loading.
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13. Add of 75 µl sample to the flow cell via the SpotON sample port in a dropwise
fashion.
14. Ensure each drop flows into the port before adding the next.
15. Gently replace the SpotON sample port cover, making sure the bung enters the
SpotON port, close the priming port and replace the MinION lid.
F) Start the sequencing run
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Data Base Accession,Serotype DQ409184,FMDV-C






































































Data analysis Step I
Start of the MinKNOW program: User interface of the MinKNOW program, with mandatory
fields to fill out. Red frame shows settings for sequencing.
Data analysis Step II
Sequencing run: MinKNOW interface for monitoring of sequencing run. Green dots show active nanopores
for sequencing.
ffline data anal i  o ed e of t e  e en in   
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Data analysis Step III
Processing sequencing files: from Fast5 to FASTA reads using ALBACORE.
Data analysis Step IV
BLAST search: Reads yielded from Barcode 1 sequencing files. In red frame, settings for MEGABLAST 
algorithm in Geneious.
86
Data analysis Step V
List of reads aligned to local database.
Data analysis Step VI
View on Query-centric alignment of sequences from local database to a single read.
87
Data analysis Step VII
Summary of all alignments produced.
88
Chapter VIII: Appendix 
 89 
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Table S1: Experimentally identified ATRs:  Comprehensive List. IgG	 IgM 		
ATR	Nr.							Spot	number				 Sequence	Number	 Accession	 Code 	 Sequence	
25	 1145	 25-39	 2,3,4	 SPFGGLKRLPAGLLL 
Eu	 Africa	 Brazil	
Detection		 			Detection						 Detection 		
Eu	 Africa	 Brazil	
Detection					 Detection						 Detection 		
103	 1150	 103-117 2,3,4		











262	 88	 262-276 1,5	 VAIAWLLGSSTSQKV x		








361	 121	 361-390 1,2,3,4,5		
126	 1,2,3,4,5		











499	 167	 499-513 1,2,3,4,5		
526	 176	 526-540 1,2,3,4,5		












PAETLHGTVTVEVQY x	 x	 x		
TLHGTVTVEVQYAGT x	 x	 x		





655	 219	 655-669 1,2,3,4,5		 TENSKMMLELDPPFG 
TVEVQYAGTDGPCKV x	 x		
676	 226	 676-690 1,5		
718	 240	 718	 1,5		
722	 1244	 722-735 2,3,4		
742	 248	 742-771 1,2,3,4,5		
252	 1,5		
1250	 2,3,4		
799	 1268	 799-813 2,3,4		




IGTLLVWLGLNTKNG x	 x	 x	 x	 x	 x		
LLMWLGLNTKNGSIS x		
SKKETRCGTGVFVYN x		












898	 1287	 898	 5		
931	 1296	 931-945 2,3,4,5		
967	 1298	 967-981 2,3,4		












1177	 1329	 1177-1191	 2,3		
LEIRFEECPGTKVHV x		
STSMAVLVAMILGGF x		























x	 x	 x	 x	 x		
x	 x	 x	 x	 x		
x	 x	 x	 x	 x		
















1726	 567	 1726-1740	 1,2,3,4,5		
1741	 581	 1741-1755	 1,2,3,4,5		
1780	 1408	 1780-1794	 2,3,4		
1840	 1409	 1840-1857	 3		
1410		 3		














1282		 1360		 1282-1305		 5		
1362		 5		
1363		 5		
1309		 1364		 1309-1326		 2,3,4,5		
438		 1		
1441		 481		 1441-1461		 1,2,3,4,5		
482		 1,5		
483		 1,5		

































































1888	 630	 1888-1902	 1,5	 TFETEFQKTKNQEWD x	
1415	 2,3,4	 TFETEFQKTKHQEWD 
1969	 1425	 1969-1983	 2,3,4	 YLYGGGCAETDEDHA 
2029	 677	 2029-2043	 1,2,3,4,5	 TFVELMKRGDLPVWL x x	
2062	 688	 2062-2082	 1,2,3,4,5	 DGTTNNTIMEDSVPA x	
690	 1,5	 TIMEDSVPAEVWTKY x	
2095	 699	 2095-2109	 1,2,3,4,5	 ARVCSDHAALKSFKE x x	
2170	 724	 2170-2184	 1,2,3,4,5	 IMLLGLLGTVSLGIF x	 x x	
2203	 735	 2203-2217	 1,2,3,4,5	 LGASAWLMWLSEIEP x x	
2308	 1453	 2308-2322	 2,3,4	 YAALTTFITPAVQHA 
2326	 776	 2326-2358	 1,2,3,4,5	 SYNNYSLMAMATQAG x	
777	 1,2,3,4,5	 NYSLMAMATQAGVLF x	
1457	 2,3,4,5	 VLFGMGKGMPFYAWD x	
1458	 2,3,4,5	 GMGKGMPFYAWDFGV x x	
2401	 801	 2401-2424	 1,2,3,4,5	 QKRTAAGIMKNPVVD 
802	 1,2,3,4,5	 TAAGIMKNPVVDGIV 
803	 1,2,3,4,5	 GIMKNPVVDGIVVTD 









2431	 1473	 2431-2445	 5	 VEKKMGQVLLIAVAV x	
2446	 816	 2446-2460	 1,5	 SSAVLLRTAWGWGEA x	
1478	 SSAILSRTAWGWGEA 
2470	 824	 2470-2487	 1,2,3,4,5	 TLWEGSPNKYWNSST 
825	 1,2,3,4,5	 EGSPNKYWNSSTATS 
x	 x	 x x	
x	 x x	
2536	 847	 2536-2568	 1,2,3,4,5	 SALEFYSYKKSGITE 
848	 1,2,3,4,5	 SYKKSGITEVCREEA x	 x x	
x	 x x	
x	 x x	
849	 1,2,3,4,5	 KSGITEVCREEARRA 
850	 1,2,3,4,5	 ITEVCREEARRALKD 
851	 1,2,3,4,5	 VCREEARRALKDGVA 
852	 1,2,3,4,5	 EEARRALKDGVATGG 
x	 x	 x x	
x	 x x	
x	 x	 x	 x x	
x	 x	 x	 x x	
2611	 1497	 2611-2625	 2,3,4	 RKVQEVKGYTKGGPG x	 x	 x	 x x	
2668	 1502	 2668-2682	 2,3,4	 SSPEVEEARTLRVLS x	
2791	 1529	 2791-2817	 2,3,4	 MKIIGNRIERIRSEH 
1533	 2,3,4	 SEHAETWFFDENHPY 
2836	 1540	 2836-2850	 2,3,4,5	 SLINGVVRLLSKPWD 
2866	 956	 2866-2880	 1,2,3,4,5	 YGQQRVFKEKVDTRV x	 x x	 x	 x x	
2926	 976	 2926-2940	 1,2,3,4,5	 LGAIFEEEKEWKTAV x	 x x	
2956	 1561	 2956-2970	 2,3,4	 REHHLRGECQSCVYN x	 x x	 x	 x x	
3037	 1570	 3037-3069	 2,3,4	 EEMSRIPGGRMYADD 
1590	 5	 EEMSQAPGGKMYADD 
x x	
x	 x	 x x	
1591	 5	 SQAPGGKMYADDTAG x	
1019	 1,5	 WDTRISKFDLENEAL x	
3097	 1594	 3097-3111	 2,3,4	 VLRPAEKGKTVMDII x	 x	 x x	
3169	 1607	 3169-3192	 5	 GWDGLKRMAVSGDDC 
1608	 5	 GLKRMAVSGDDCVVK 
1060	 1,2,3,4,5	 VSGDDCVVKPIDDRF 
x	 x x	
x	 x x	
3190	 1064	 3190-3204	 1,2,3,4,5	 DRFAHALRFLNDMGK x	
3205	 1609	 3205-3219	 2,3,4	 VRKDTQEWKPSTGWD x	 x x	
3229	 1616	 3229-3246	 2,3,4	 HHFNKLHLKDGRSIV x	
1078	 1,5	 NKLYLKDGRSIVVPC 
3286	 1619	 3286-3300	 2,3,4	 HRRDLRLMANAICSS x	




3325	 1109	 3325	 1,5	 EDMLMVWNRVWIEEN 
3382	 1638	 3382-3405	 2,3	 KNTVNMVRRIIGDEE x	
1639	 4	 KNTVNMVRRIIGEEE 
1640	 3	 VNMVRRIIGEEEKYM 
1641	 3	 VRRIIGEEEKYMDYL 
1642	 3	 IIGEEEKYMDYLSTQ 
x	
x	 x	 x	 x x	
x	 x	 x	 x x	





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S4: Comparing sets of experimentally identified ATRs (this study) and of those 
predicted on the basis by theoretical considerations a,b) 
ATR Sequence Region 




Xu et. al, 
(AMQ48981.1) 
(a) 
Homan et. al, 
(KF383119.1) 
(b) 
ATRs identified via ZIKV microarray chips, not predicted by Xu et. al., and Homan et. al. 
25 SPFGGLKRLPAGLLL C 25-39 25-39
361 DSRCPTQGEAYLDKQSDTQYVCKRTLVDRG E 361-390 361-390
799 SKKETRCGTGVFVYN NS1 799-813 803-817
817 AWRDRYKYHPDSPRRLAAAVKQAW NS1 817-840 821-844
1024 DGVEESDLIIPKSLA NS1 1024-1038 1028-1042 
1177 STSMAVLVAMILGGF NS2 1177-1191 1181-1195 
1213 GGDVAHLALIAAFKVRPA NS2 1213-1230 1217-1234 
1282 RAMAVPRTDNIALAILAALTPLAR NS2 1282-1305 1286-1309 
1309 LVAWRAGLATCGGFMLLS NS2 1309-1326 1313-1330 
1441 RLDVALDESGDFSLVEEDGPP NS2 1441-1461 1445-1465 
1540 QEGVFHTMWHVTKGSALRSGEGRLDPY NS3 1540-1566 1544-1570 
1585 AAWDGLSEVQLLAVPPGE NS3 1585-1602 1589-1606 
1618 DGDIGAVALDYPAGT NS3 1618-1632 1622-1636 
1654 IKNGSYVSAITQGKREEETPVECFEPSMLK NS3 1654-1683 1658-1687 
1726 VAAEMEEALRGLPVR NS3 1726-1740 1730-1744 
1741 YMTTAVNVTHSGTEI NS3 1741-1755 1745-1759 
1780 YIMDEAHFTDPSSIA NS3 1780-1794 1784-1798 
1840 ERAWSSGFDWVTDYSGKT NS3 1840-1857 1844-1861 
1870 IAACLTKAGKRVIQL NS3 1870-1884 1874-1888 
1888 TFETEFQKTK(N/H)QEWD NS3 1888-1902 1892-1906 
1969 YLYGGGCAETDEDHA NS4 1969-1983 1973-1987 
2029 TFVELMKRGDLPVWL NS4 2029-2043 2033-2047 
2062 DGTTNNTIMEDSVPAEVWTKY NS4 2062-2082 2066-2086 
2095 ARVCSDHAALKSFKE NS4 2095-2109 2099-2113 
2170 IMLLGLLGTVSLGIF NS4 2170-2184 2174-2188 
2203 LGASAWLMWLSEIEP NS4 2203-2217 2207-2221 
2308 YAALTTFITPAVQHA NS4 2308-2322 2312-2326 
2326 SYNNYSLMAMATQAGVLFGMGKGMPFYAWDFGV NS4 2326-2358 2330-2362 
2401 QKRTAAGIMKNPVVDGIVVTDIDT NS4 2401-2424 2405-2428 
2431 VEKKMGQVLLIAVAV NS4 2431-2445 2435-2449 
2446 SSA(V/I)L(S/L)RTAWGWGEA NS4 2446-2460 2450-2464 
2470 TLWEGSPNKYWNSSTATS NS4 2470-2487 2474-2491 
2536 SALEFYSYKKSGITEVCREEARRALKDGVATGG NS5 2536-2568 2540-2572 
2611 RKVQEVKGYTKGGPG NS5 2611-2625 2615-2629 
2668 SSPEVEEARTLRVLS NS5 2668-2682 2672-2686 
2791 MKIIGNRIERIRSEHAETWFFDENHPY NS5 2791-2817 2795-2821 
2836 SLINGVVRLLSKPWD NS5 2836-2850 2840-2854 
2866 YGQQRVFKEKVDTRV NS5 2866-2880 2870-2884 
2926 LGAIFEEEKEWKTAV NS5 2926-2940 2930-2944 
2956 REHHLRGECQSCVYN NS5 2956-2970 2960-2974 
3037 
EEMS(R/Q)(I/A)PGG(R/K)MYADDTAGWDTRISKFDL
ENEAL NS5 3037-3054 3041-3058 
3097 VLRPAEKGKTVMDII NS5 3097-3111 3101-3115 
3169 GWDGLKRMAVSGDDCVVKPIDDRF NS5 3169-3192 3173-3196 
3190 DRFAHALRFLNDMGK NS5 3190-3204 3194-3208 
3205 VRKDTQEWKPSTGWD NS5 3205-3219 3209-3223 
96
3229 HHFNKL(H/Y)LKDGRSIVVPC NS5 3229-3246 3233-3250 
3286 HRRDLRLMANAICSS NS5 3286-3300 3290-3304 
3298 CSAVPVDWVPTGRTTWSIHGKGEW NS5 3298-3321 3302-3325 
3325 EDMLMVWNRVWIEEN NS5 3325-3339 3329-3343 
3382 KNTVNMVRRIIG(D/E)EEKYMDYLSTQ NS5 3382-3405 3386-3409 
ATRs identified via ZIKV microarray chip and predicted by Xu et. al., and/or Homan et. al. 
103 EKKRRGADTSVGIVG C 103-117 100-114 100-110 100-107
130 
RRGSAYYMYLDRNDAISF(A/P)TTLG(V/M)NKC(H/Y)
(V/I)QIMDLGHMCD prM 130-172 127-169 135-139/143-148 139-143
262 VAIAWLLGSSTSQKV prM 262-276 262-276 269-273
304 GMSGGTWVDIVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRS E 304-348 304-348 344-349 305-309
388 DRGWGNGCGLFGKGS E 388-402 388-402 387-427
433 VHGSQHSGMIVNDIGHETDENRAKVEITPNSPRAEAT E 433-469 433-469 433-435/436-448 455-459/464-472
499 VHKEWFHDIPLPWHA E 499-513 503-517 494-515
526 EALVEFKDAHAKRQT E 526-540 530-544 532-536
592 SLCTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCKV E 592-627 596-631 608-616
655 TENSKMMLELDPPFG E 655-669 659-673 655-666/670-682 653-663
676 GVGDKKITHHWHRSG E 676-690 680-694 670-682
718 GSVGGVFNSLGKGIH E 718-732 722-736 717-726 725-729
722 GGALNSLGKGIHQIF E 722-735 726-739 725-729
742 LFGGMSWFSQILIGTLLMWLGLNTKNGSIS E 742-771 746-775 746-752/756-759
898 VNGLPHGWKAWGKSY NS1 898-912 902-916 899-904/912-915
931 KECPLKHRAWNSFLV NS1 931-945 935-949 932-935/935-938
967 LECDPAVIGTAVKGK NS1 967-981 971-985 968-972
1045 NTREGYRTQVKGPWHSEELEIRFEECPGTKVHV NS1 1045-1077 1049-1081 1043-1051 
ATRs only predicted by Xu et. al., and/or Homan et. al. but not found in this study 
/	 GGFRIVNMLKR C 9-19 9-19 9-19
/	 SVGKK C 71-75 71-75 71-75
/	 NARK C 96-99 96-99 96-99
/	 DEGVEPDDV prM 179-187 179-187 179-187
/	 ARRSRRA prM 210-216 210-216 210-216
/	 SHSTRKL prM 221-227 221-227 221-227
/	 IGVSNRDFVEGMSGGTWVDVVL prM 294-315 294-315 294-315
/	 QPENL E 421-424 421-424 421-424
/	 RIMLS E 428-432 428-432 428-432
/	 SQHSGMIVNDTG E 436-448 436-448 436-448
/	 ATLGG E 464-468 468-472 468-472
/	 AGADTG E 513-518 517-522 517-522
/	 GTPH E 518-521 522-525 522-525
/	 VVLGSQEGAVHTALAGAL E 542-559 545-562 545-562
/	 EMDGAKGRLS E 562-570 565-573 565-573 571-579
/	 HLKCRLKMDKL E 574-584 577-587 577-587
/	 PCKVPAQMAV E 624-633 628-637 628-637
/	 VGRLITANP E 641-649 645-653 645-653
/	 HQIFG E 732-736 736-740 736-740
/	 DVGC NS1 791-794 795-798 795-798
/	 PVPVNE NS1 895-900 899-904 899-904
/	 SYFVRAAKT NS1 911-919 915-923 915-923
/	 DTLK NS1 928-931 932-935 932-935
/	 LKVREDYSLE NS1 959-968 963-972 963-972
97
/	 WYGMEIRP NS1 1120-1127 1124-1131 1124-1131 
/	 VLMTICGMN NS2B 1470-1478 1474-1482 1474-1482 
/	 PFAA NS2B 1483-1486 1487-1490 1487-1490 
/	 ALNTFTNLVVQLIRNMEAE NS5 3126-3144 3130-3148 3130-3148 
a) Xu X, Vaughan K, Weiskopf D, Grifoni A, Diamond MS, Sette A, Peters B. 2016.
Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to
Epitopes in Other Flavivirus Species. PLoS Curr 8.
b) Homan EJ, Malone RW, Darnell SJ, Bremel RD. 2016. Antibody mediated epitope
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